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7ABSTRACT
Idiopathic pulmonary fibrosis (IPF) is a dismal disease with an unknown aetiology and poor 
prognosis. It is often diagnosed late when treatment options are minimal. Differentiating idio-
pathic pulmonary fibrosis from non-specific interstitial pneumonia can be difficult and there is 
a need for new diagnostics markers. The aim of the study was to explore new diagnostic tools 
and potential treatment options for IPF. 
Mesenchymal cell migration and proliferation are known to be associated with the activation of 
profibrogeneic growth factors and their tyrosine kinase receptors, matrix metalloproteinase ex-
pression and cytokine-induced cell proliferation. The study utilized patient material obtained 
from bronchoalveolar lavage (BAL), diagnostic biopsies or lung transplantation. Human pul-
monary fibroblast cell cultures were propagated from commercial IPF cell lines as well as from 
patient material to assess fibroblast proliferation and migration in vitro. Asbestos-induced pul-
monary fibrosis in mice was used as an experimental animal model of IPF. The possible mark-
ers for IPF were scanned by immunohistochemistry, RT-PCR, ELISA and western blot. 
Recent microarray studies have raised a number of potential markers that could serve as help-
ful tools for the diagnosis of IPF. We measured matrix metalloproteinase-7 (MMP-7) protein 
levels in the BAL fluid of patients with idiopathic interstitial lung diseases in order to deter-
mine whether it could be used in the differential diagnostics, especially in the differentiation of 
IPF from other interstitial lung disorders. MMP-7 was similarly elevated in the BAL fluid of 
all these disorders and thus cannot be used as a differential diagnostic marker for IPF.
The bone morphogenetic protein-4 inhibitor gremlin was found to be highly upregulated in the 
IPF lungs and IPF fibroblasts. When gremlin expression and localization was assessed in de-
tail, it was detected in the thickened IPF parenchyma and endothelium of small capillaries, 
whereas in non-specific interstitial pneumonia it was localized predominantly in the alveolar 
epithelium. Although some overlapping in the staining patterns was observed, this suggests 
that parenchymal gremlin immunoreactivity might indicate IPF-type interstitial pneumonia. 
Gremlin mRNA levels were higher in patients with end-stage fibrosis suggesting that gremlin 
might represent a marker for more advanced disease. 
Characterization of the fibroblastic foci in the IPF lungs showed that immunoreactivity to 
platelet-derived growth factor (PDGF) receptor- and PDGF receptor- was elevated in 
IPF/UIP parenchyma, but the fibroblastic foci displayed only minor immunoreactivity to the 
PDGF receptors or peroxiredoxin (Prx) II. There was no major Prx II oxidation in IPF/UIP 
when compared to the normal lung and Prx II localized mainly outside the fibloblastic foci.
Ki67 positive cells were also observed predominantly outside the fibroblastic foci, suggesting 
that the fibroblastic foci may not be composed of actively proliferating cells. When inhibition 
of profibrotic PDGF-signalling by imatinib mesylate was assessed, imatinib mesylate reduced 
asbestos-induced pulmonary fibrosis in mice as well as human pulmonary fibroblast migration 
in vitro but it had no effect on the lung inflammation.
8INTRODUCTION
Idiopathic interstitial pneumonias (IIP) are diffuse parenchymal lungs diseases with an unkown 
aetiology (ATS/ERS 2002). A common theme for these diseases is a varying degree of in-
flammation and fibrotic lung tissue (Kim et al. 2006). Idiopathic pulmonary fibrosis (IPF) is 
the most common of the idiopathic interstitial lung diseases (Kim DS et al. 2006). Most com-
monly it affects most commonly people over 50 years with the prevalence and incidence being
higher in men (Coultas et al. 1994). The typical histopathological pattern of IPF seen in a sur-
gical biopsy is termed usual interstitial pneumonia (UIP). 
Since IPF is a progressive disease without an effective cure, a precise diagnosis is crucial for 
future prognosis and selecting suitable treatment. Differential diagnosis between IPF and fi-
brotic non-specific interstitial pneumonia (NSIP) can, however, be very difficult (Dempsey et 
al. 2006, Kim DS et al. 2006). The classification of UIP and NSIP as separate clinical entities 
was recently questioned and the possibility has been raised that UIP and NSIP may share a 
common clinical phenotype and pathogenesis (Maher et al. 2007).
The pathogenesis of IPF is believed to be initiated after an alveolar epithelial injury that leads 
to inadequate repair, collagen accumulation, fibroblast proliferation and failure to replace the 
affected epithelium (Selman and Pardo 2002, 2006). A network of growth factors and cytoki-
nes such as transforming growth factor (TGF)- and platelet-derived growth factor (PDGF) 
mediate complex interactions between various cell types and activate signalling pathways that 
result in the formation of persistent fibrosis (Allen and Spiteri 2002). This will ultimately lead 
to the destruction of normal lung architecture, loss of alveolar surface area and impairment in 
gas exchange (Katzenstein and Myers 1998). 
TGF- is upregulated in fibrotic lungs (Bergeron et al. 2003) where it stimulates the differen-
tiation of myofibroblasts (Tomasek et al. 2002, Evans et al. 2003) and protects them against 
apoptotic stimuli (Zhang and Phan 1999). Bone morphogenetic proteins (BMPs) are negative 
regulators of intracellular TGF- signalling (Chen D et al. 2004) and BMP-4 –signalling is in 
turn negatively regulated by gremlin protein (Topol et al. 1997, Shi et al. 2001). 
Matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMP) 
participate in the remodelling of the extracellular matrix (ECM) and elevated production of 
TIMPs contributes to the ECM accumulation seen in IPF (Selman et al. 2000, Pardo and Sel-
man 2006).
Peroxiredoxins (Prx) are antioxidant enzymes that contribute to intracellular signalling by re-
moving H2O2 (Wood et al. 2003) and function as negative regulators of PDGF signalling (Choi 
et al. 2005). Prx II deficiency in turn results in increased production of H2O2 and enhanced ac-
tivation of PDGF receptors. 
The present study attempted to identify new diagnostic markers for IPF that are involved in the 
complex network of signalling events that lead to persistent pulmonary fibrosis. Elevated 
MMP-7 protein levels in the bronchoalveolar lavage (BAL) fluid of patients with idiopathic in-
9terstitial pneumonias were detected but this could not be used to differentiate between the dis-
orders. Gremlin mRNA expression was elevated in IPF biopsies and gremlin protein localiza-
tion differed between IPF and NSIP. Parenchymal protein localization seemed to suggest an 
IPF-type idiopathic interstitial pneumonia while elevated gremlin mRNA expression was ob-
served especially in the advanced stages of the disease. The evaluation of the fibroblastic foci 
which typically occur in IPF showed only weak expression of PDGF receptors and oxidative 
markers. The value of inhibition of profibrotic PDGF-signalling in the prevention of the pro-
gression of IPF was evaluated with human IPF fibroblasts and asbestos-induced pulmonary fi-
brosis in mice. This led also to the characterization and assessment of the imatinib mesylate 
target molecules PDGF receptors, Abl and c-kit in normal and IPF lungs.
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REVIEW OF THE LITERATURE
1. Idiopathic pulmonary fibrosis
1.1. Classification
Idiopathic interstitial pneumonias (IIP) are diffuse parenchymal lung diseases with varying de-
gree of inflammation and fibrosis. Their aetiology is unknown and the current classification is 
based on histopathology (ATS/ERS 2002) (Table 1). Idiopathic pulmonary fibrosis (IPF) is the 
most common IIP, with a relative frequency of 47-64% of all IIPs (Kim DS et al. 2006). IPF is
the term used for the clinical diagnosis, whereas the typical histopathological pattern of the 
disease seen in a surgical biopsy is termed usual interstitial pneumonia (UIP). ´Usual´ refers to 
the common nature of this histological pattern among the IIPs, while ´pneumonia´ denotes the 
role of inflammation rather than infection (Dempsey et al. 2006). Although the terms IPF and 
UIP are often used as synonyms, the UIP-type pattern is not restricted to IPF. It can also be 
found in the lungs of patients with asbestosis, connective tissue diseases and in some drug-
induced lung diseases. 
Table 1.  Classification of idiopathic interstitial pneumonias. 
The definition of IPF was introduced in 1944 when Louis Hamman and Arnold Rich published a study of patients 
suffering from acute diffuse interstitial lung fibrosis (Hamman and Rich 1944). Liebow and Carrington later sepa-
rated IIPs into five subtypes based on their histopathological appearance (Liebow and Carrington 1969). This 
classification was refined in 1998 when Katzenstein and Myers described four IIP subtypes (Katzenstein and 
Myers 1998). The most recent classification of IIPs is the international consensus statement by the American Tho-
racic Society (ATS) and European Respiratory Society (ERS) (ATS/ERS 2002). It is based on histopathology and 
divides the IIPs into seven clinicopathological entities that are listed here in the order of their frequency. 
Hamman, 
Rich (1944)
Liebow, Carrington (1969) Katzenstein, Myers (1998) American Thoracic Society 
and European Respiratory 
Society (2002)
• Hamman-
Rich 
syndrome 
(IPF)
• Usual interstitial 
pneumonia (UIP)
• Bronchiolitis obliter-
ans interstitial pneumo-
nia (BIP)
• Desquamative inter-
stitial pneumonia (DIP)
• Giant cell interstitial 
pneumonia (GIP)
• Lymphocytic intersti-
tial pneumonia (LIP)
• UIP
• DIP
• Acute interstitial pneu-
monia (AIP)
• Non-specific interstitial 
pneumonia (NSIP)
• IPF (histopathologi-
cally UIP)
• NSIP
• Respiratory bronchio-
litis-associated intersti-
tial lung disease (RB-
ILD)
• DIP
• Cryptogenic organiz-
ing pneumonia (COP)
• AIP
• LIP
1.2. Epidemiology and aetiology
Cases of IPF have been reported worldwide and the patients are mainly over 50 years old, with 
the mean age of onset 67-69 (Coultas et al. 1994). There is a difference in the prevalence of 
IPF between sexes, i.e. 20/100 000 for males and 13/100 000 for females. The incidence of IPF 
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is also higher for males (approximately 11/100 000 per year) than for females (7/100 000 per 
year) (Coultas et al. 1994). In Finland, the nationwide prevalence of IPF is estimated to be 16-
18/100 000 (Hodgson et al. 2002). 
There is evidence for an involvement of both environmental and genetic factors in the devel-
opment of IPF. Occupational and/or environmental exposure to agents such as metal or wood 
dust (Baumgartner et al. 2000), cigarette smoke (Baumgartner et al. 1997) or infectious agents 
are regarded as risk factors for developing IPF (ATS/ERS 2000). Reactive oxygen species and 
increased oxidative stress have also been suggested to play a role in the pathogenesis and pro-
gression of IPF and an oxidant/antioxidant imbalance can affect the gene expression of several 
profibrotic factors (Kinnula and Myllärniemi 2008). A high prevalence of acid gastro-
oesophageal reflux has also been observed among patients with IPF (Raghu et al. 2006).
Familial IPF is usually considered as rare (Steele et al. 2005). The clinical, pathological and 
radiological findings have been reported to be similar in familial IPF and nonfamilial disease 
and survival was similar in both of them (Lee et al. 2005). In Finland, familial IPF accounts for 
approximately 3.5% of all of the IPF cases (Hodgson et al. 2002) and a susceptibility gene 
(ELMOD2) for familial pulmonary fibrosis has been identified (Hodgson et al. 2006). Al-
though the biological functions of ELMOD2 in the lung remain unknown, decreased gene ex-
pression in patients with familial pulmonary fibrosis suggests its involvement in familial IPF 
(Hodgson et al. 2006). Gene expression profiling can be used to identify target genes involved 
in fibrosis and tissue remodelling (Kaminski and Rosas 2006, Selman et al. 2006). However, 
no suitable gene associations with sporadic IPF have been found, and familial assays and stud-
ies may provide better candidate genes. In a recent gene expression study, fewer differences 
were found between non-specific interstitial pneumonia (NSIP) and UIP than familial vs. spo-
radic IIPs (Yang et al. 2007). 
1.3. Diagnosis
Patients with IPF have typically experienced shortness of breath and chronic cough for at least 
six months before diagnosis. Pulmonary function tests reveal restriction with reduced vital ca-
pacity, often accompanied by an increased ratio of forced expiratory volume in one sec-
ond/forced vital capacity (FEV1/FVC) and reduced diffusing capacity for carbon monoxide 
(DLCO) (Egan et al. 2005). In one study, analysis of BAL fluid revealed increased numbers of 
neutrophils (Ryu et al. 2007). 
The chest radiograph often lacks diagnostic specificity and it may be interpreted as being nor-
mal in the earlier stages of the disease, though it will show changes in the basal and subpleural 
regions as the disease progresses (Dempsey et al. 2006). High-resolution computed tomogra-
phy (HRCT) has proven to be an accurate and sensitive non-invasive diagnostic tool in the spe-
cific diagnosis of IPF (Lynch et al. 2005). HRCT uses thin tissue sections (1-2 mm) and allows 
abnormalities in the lung parenchyma to be identified even when they do not appear in the 
chest radiographs. Typical HRCT features of an IPF patient include bilateral changes, lower 
lobe predominance, reticular abnormalities, lack of ground-glass opacity, peripheral honey-
combing and traction bronchiectasis (Dempsey et al. 2006) (Figure 1).
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Figure 1. Typical HRCT image (on the left) of idiopathic pulmonary fibrosis and a surgical lung biopsy exhibit-
ing features of usual interstitial pneumonia. The red colour on the right indicates myofibroblasts that form fibro-
blastic foci.
Definitive differential diagnosis of IPF can be made from a surgical lung biopsy that is usually 
taken using video-assisted thoracoscopic surgery rather than open thoracotomy in order to re-
duce the risks associated with the procedure. Multiple samples from different lobes of the lung 
should be taken due to the patchy nature of the disease and the possibility of UIP and NSIP co-
existing in the same lung (Flaherty et al. 2001a, Monaghan et al. 2004). The histopathological 
pattern of UIP typically comprises of areas of normal lung architecture with scattered areas of 
fibroblasts and collagen deposition, the fibroblastic foci (Kuhn et al. 1989), and honeycombing 
(Katzenstein and Myers 1998) (Figure 1). Alveolar walls are thickened and heterogeneous hy-
perplasia of alveolar epithelial cells or type 2 pneumocytes can be seen (Honda et al. 2006). In-
flammation is often absent or restricted to small areas (Katzenstein and Myers 1998) and it 
consists mostly of lymphocytes and plasma cells but there are only occasional neutrophils and 
eosinophils. 
An accurate diagnosis of IIP demands close collaboration by the clinician, radiologist and pa-
thologist. There is still significant interobserver disagreement between pathologists and this is 
compounded by the histological variability within individual patients. The clinical features of 
NSIP are similar to IPF with shortness of breath and cough (Martinez 2006) and both NSIP and 
UIP patterns can be found in biopsies from the same patient (Flaherty et al. 2001a, Monaghan 
et al. 2004) which complicates their differential diagnosis. The transcriptional profiles of IPF 
and NSIP have also been shown to be similar (Kaminski and Rosas 2006) and only minor gene 
expression changes have been identified (Yang et al. 2007). NSIP is subdivided into the cellu-
lar form that is characterized by mild to moderate chronic interstitial inflammation and fibrotic 
form that exhibits dense or loose interstitial fibrosis (ATS/ERS 2002). It has been proposed 
that the fibrotic pattern of NSIP may in fact be an early, inactive form of UIP and that NSIP 
may progress to IPF (Flaherty et al. 2001a), but further studies have found no evidence of this 
process (Katzenstein et al. 2002). However, a recent report questioned the definition of UIP 
and NSIP as separate clinical entities and suggested that idiopathic UIP and NSIP share a 
common clinical phenotype and pathogenesis (Maher et al. 2007). 
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 1.4. Prognosis 
The overall prognosis of IPF is poor (Kim DS et al. 2006). Median survival after diagnosis is 
only 2-4 years, although there is extensive variation between patients. Patients can experience 
periods of relative stability followed by sudden and unexpected worsening. These acute exac-
erbations have no identifiable cause and can ultimately lead to the death of the patient (Collard 
et al. 2007). Factors affecting poor patient survival include increased age, male sex, smoking, 
abnormalities in lung function parameters and radiography, as well as neutrophilia or eosino-
philia in BAL fluid and UIP-type histology (King et al. 2001, Flaherty et al. 2003). An exten-
sive accumulation of fibroblastic foci in the surgical biopsy has been shown to correlate with 
decreased FVC and DLCO and is associated with higher mortality (Nicholson et al. 2002, Ti-
itto et al. 2006). Comparison of the effects of lung transplantation on the survival and progno-
sis of IPF and non-IPF patients revealed poorer survival for IPF patients although it was im-
proved by double lung transplant (Mason et al. 2007). 
2. Mechanism of pulmonary fibrosis 
2.1. Wound healing
Damaged epithelial and/or endothelial cells release inflammatory mediators that trigger the 
wound healing process and recruit and activate inflammatory cells, fibroblasts and extracellular 
matrix (ECM) deposition (Selman and Pardo 2006). When platelets became exposed to ECM 
components they iniate clot formation. Myofibroblasts, epithelial and endothelial cells produce 
proteolytic matrix metalloproteinases (MMPs) that degrade basement membrane and thus en-
hance inflammatory cell migration to the site of injury (Selman et al 2000). Growth factors, cy-
tokines and chemokines all stimulate macrophage and neutrophil recruitment. Macrophages 
take up tissue particles and apoptotic neutrophils as well as producing chemotactic agents for 
endothelial cells that in turn help generate new blood vessels (Wynn 2008). Inflammatory cells, 
such as lymphocytes, also became activated and secrete profibrotic cytokines that further 
stimulate macrophages and fibroblasts (Wynn 2008). Activated myofibroblasts enhance wound 
contraction while epithelial and endothelial cells replace and regenerate the damaged tissue 
(Selman and Pardo 2006). However, if the epithelial injury persists, then this wound healing 
process cannot be completed and instead, myofibroblasts produce increased amounts of ECM 
components and the imbalance between ECM degradation and regeneration evokes persistent 
fibrotic scar (Wynn 2008).
2.2. Epithelial injury 
Unlike in many other interstitial lung diseases, no clear or identifiable inflammatory process 
can be seen in the early stages of IPF (Bringardner et al. 2008). Thus, the current hypothesis 
for the pathogenesis of IPF is based on epithelial injury, which leads to the apoptosis of alveo-
lar epithelial cells (Barbas-Filho et al. 2001) and disruption of normal alveolar epithelium 
structure (Selman and Pardo 2002, 2006). The events leading to abnormal repair responses are 
still not understood and it is possible that a combination of different types of epithelial injury 
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initiate the disease. Viral infection has been proposed as a source of repetitive injury to the al-
veolar epithelium and Epstein-Barr virus (Egan et al. 1995) as well as herpes viruses (Tang et 
al. 2003) have been found in the lung tissue of patients with IPF. Mechanical injury to epithe-
lial cells in an experimental co-culture of airway epithelial cells and fibroblasts induced myofi-
broblast differentiation and increased collagen production, suggesting that even a mechanical 
injury could cause tissue remodelling (Morishima et al. 2001). Inhaled oxygen and reactive 
oxygen species, tobacco smoke and air pollutants can also affect the alveolar epithelium and 
evoke an oxidant/antioxidant imbalance, which has been associated with pulmonary fibrosis 
(Kinnula and Myllärniemi 2008).
The severity and outcome of the fibrotic processes depend on the ability of the alveolar epithe-
lial cells to proliferate and repair the damages. Growth factors such as transforming growth 
factor (TGF)-, platelet-derived growth factor (PDGF), fibroblast growth factor (FGF) and in-
sulin-like growth factor (IGF)-1 activate tyrosine kinase signalling pathways that recruit fibro-
blasts, promote epithelial cell regeneration and migration as well as hyperplastic alveolar 
epithelial cells, type 2 pneumocytes (Allen and Spiteri 2002). Osteopontin is a cytokine that 
induces proliferation and migration of fibroblasts and epithelial cells. It has been determined to 
be up-regulated in the IPF lung and expressed by alveolar epithelial cells (Pardo et al. 2005). 
Vascular endothelial cell injury and anti-endothelial cell antibodies in the serum of patients 
with IPF have also been associated with the evolution of IPF (Magro et al. 2006).
An important factor in the development of pulmonary fibrosis is loss of integrity of the subepi-
thelial basement membrane (Hayashi et al. 1996). Gaps in the epithelial basement membrane 
allow proliferating interstitial fibroblasts to migrate into the alveolar space. Alveolar epithelial
cells express MMP-1 and MMP-7; these two enzymes are known to be involved in wound 
healing and possibly are involved in fibroblast and epithelial cell migration (Zuo et al. 2002). 
Alveolar epithelial cells and myofibroblasts also express MMP-2 and MMP-9 (Hayashi et al. 
1996, Selman et al. 2000) that may enhance fibroblast migration and ECM accumulation by 
degrating the basement membrane (Figure 2).
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Figure 2. Activated epithelial cells secrete numerous mediators that induce fibroblast proliferation, migration and 
ECM accumulation after alveolar epithelium injury. Modified from Gharaee-Kermani et al. 2007.
2.3. Alveolar epithelial cells
Alveolar basement membrane and the surface of the alveoli are lined with alveolar epithelial 
cells or pneumocytes (Selman and Pardo 2006). Over 90% of the alveolar surface is covered by 
type 1 pneumocytes. These cells form a thin surface layer for gas exchange and have surface 
receptors for a variety of ECM molecules, growth factors and cytokines. Type 1 pneumocytes 
are sensitive to damage but their ability to to be repaired is poor (Gharaee-Kermani et al. 
2007).
Type 2 pneumocytes function as progenitor cells that can differentiate into type 1 pneumocytes 
(Kasper and Haroske 1996, Selman and Pardo 2006). This is influenced in vitro by ECM com-
ponents that determine which phenotype the differentiating type 2 pneumocytes will take (Ol-
sen et al. 2005). Typical morphological changes in the IPF epithelium include hyperplastic type 
2 pneumocytes, elongated epithelial cells that could be type 2 pneumocytes differentiating into 
type 1, flattened epithelium overlying the fibroblastic foci, bronchiolar-type epithelium lining 
airspaces and honeycombed tissue (Kasper and Haroske 1996). The ability of abnormal, hy-
perplastic type 2 pneumocytes to proliferate and restore damaged type 1 pneumocytes is se-
verely affected in IPF (Kasper and Haroske 1996). 
16
The alveolar epithelial cells produce numerous profibrotic growth factors and cytokines, such 
as PDGF (Antoniades et al. 1990), tumour necrosis factor (TNF)- (Kapanci et al. 1995) and 
TGF- (Kapanci et al. 1995, Khalil et al. 1996, Xu et al. 2003) that induce proliferation and 
migration of the underlying fibroblasts as well as ECM accumulation (Selman and Pardo 
2006). Alveolar epithelial cells also secrete angiostatic factors, such as pigment epithelium-
derived factor, which is increased in the IPF/UIP lungs and may be responsible for the de-
creased vascular density seen characteristically in the fibroblastic foci (Cosgrove et al. 2004). 
Increased epithelial cell apoptosis and decreased fibroblast and myofibroblast apoptosis are be-
lieved to take place during pulmonary fibrosis (Selman and Pardo 2002, Thannickal and 
Horowitz 2006). Epithelial cell apoptosis occurs adjacent to the myofibroblasts in the fibro-
blastic foci (Uhal et al. 1998) and it can be caused by increased production of the blood pres-
sure regulator peptide, angiotensin (Wang et al. 1999) as well as by proapoptotic Fas-signalling 
molecules (Maeyama et al. 2001), TGF-1 (Hagimoto et al. 2002) and TNF- (Wang et al. 
2000a). Oxidative stress (Kuwano et al. 2003), TGF-1-stimulated oxidant secretion by fibro-
blasts (Thannickal and Fanburg 1995, Waghray et al 2005) and reduced glutathione levels 
(Cantin et al. 1989) in the epithelial lining fluid have also been associated with epithelial dam-
age and epithelial cell apoptosis in IPF. 
2.4. Fibroblasts and myofibroblasts
Pulmonary fibroblasts exhibit phenotype diversity and different subpopulations express charac-
teristic surface markers including -smooth muscle actin (-SMA) and desmin (Zhang et al. 
1994). Pulmonary fibroblasts differ also in regard to the cell surface receptor expression, cy-
toskeleton structure and cytokine secretion (Scotton and Chambers 2007).  -SMA expressing 
myofibroblasts possess structural and functional features such as contractility that are interme-
diate between fibroblasts and smooth muscle cells (Tomasek et al. 2002). Myofibroblasts are 
the principal collagen-producing and proliferating cells in fibrotic diseases (Kuhn et al. 1989,
Zhang et al. 1994) and they form the characteristic sites of fibrosis, the fibroblastic foci 
(Katzenstein and Myers 1998). Instead of being the result of multiple local epithelial injuries, 
fibroblastic foci have been suggested to actually form a complex and interconnected reticulum 
that progresses through the lung parenchyma (Cool et al. 2006). TGF- has been shown to 
promote the differentiation of myofibroblasts from fibroblasts (Tomasek et al. 2002, Evans et 
al. 2003) and it helps them to prevail in the tissue by protecting them against apoptotic stimuli 
(Zhang and Phan 1999). In addition to growth factors, the coagulation protein, thrombin, has 
been shown induce myofibroblast differentiation in vitro (Bogatkevich et al. 2001).
The origin of the pulmonary myofibroblasts in the injured lung is still unclear, but they may 
originate from proliferating residential cells (Zhang et al. 1994), epithelial-to-mesenchymal 
transition (Willis et al. 2005, Kim et al. 2006), bone marrow-derived progenitor cells (Hashi-
moto et al. 2004) and/or circulating fibrocytes (Phillips et al. 2004). Fibrocytes form a fibro-
blast-like cell population that shares both leukocyte and connective tissue cell features and mi-
grates from blood vessels to wound sites (Bucala et al. 1994). TGF-1 induces -SMA expres-
sion and collagen production in human peripheral blood-derived fibrocytes in vitro, indicating 
that they may differentiate into myofibroblasts (Abe et al. 2001). One study with bleomycin-
induced fibrosis introduced a novel fibroblast phenotype expressing telomerase, an enzyme 
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that adds DNA sequences to the ends of replicating chromosomes and thus enables the cells to 
divide repeatedly (Nozaki et al. 2000). These cells may represent an intermediate cell type be-
tween the normal fibroblasts and highly activated myofibroblasts, but their exact role in the fi-
brotic lungs remains unclear (Nozaki et al. 2000). 
2.5. Epithelial-to-mesenchymal transition
The importance of epithelial-to-mesenchymal transition (EMT) has been recognized in cell dif-
ferentiation during organ development and tumour invasion. Epithelial cells respond to stress 
and/or injury by undergoing apoptosis, proliferating, differentiating and forming new epithe-
lium or by changing their phenotype to mesenchymal cells via EMT (Willis and Borok 2007). 
EMT is considered a source of fibroblasts and myofibroblasts in the IPF lung (Willis et al. 
2005, Kim KK et al. 2006) and it promotes pulmonary fibrosis by impairing the repair of the 
injured epithelium. During EMT, epithelial cells lose their cell-cell attachment and adopt a 
more invasive phenotype (Willis and Borok 2007). They undergo remodelling of their cy-
toskeleton, changes in protein expression (epithelial markers such as E-cadherin downregu-
lated) and eventually gain myofibroblast-specific markers (-SMA) and a fibroblast-like phe-
notype (Willis et al. 2005). Overexpression of N-cadherin, a cell adhesion molecule expressed 
mainly in migratory cells, in the alveolar epithelial cells overlying the fibroblastic foci supports 
the EMT theory (Selman et al. 2006). ECM components fibronectin and fibrin have also been 
shown to promote EMT in cultured alveolar epithelial cells (Kim KK et al. 2006).
TGF- has been shown to induce EMT both in vitro and in vivo (Kasai et al. 2005, Kim KK et 
al 2006). The relevance of this finding is further supported by the fact that the hyperplastic type 
2 epithelial cells overlying the fibroblastic foci were reported to express both epithelial and 
mesenchymal markers in human IPF/UIP lung biopsy samples (Willis et al. 2005). 
2.6. Stem cells 
Embryonic stem cells are pluripotent and can form any cell type or tissue. Adult stem cells re-
side within the tissue in various organs and are activated to differentiate and replace existing 
cells after injury. In addition, bone marrow-derived stem cells (haematopoietic, mesenchymal, 
endothelial stem cells) give rise to a variety of cells (Gharaee-Kermani et al. 2007). The possi-
ble role of stem cells in pulmonary fibrosis has been recognized (Gharaee-Kermani et al. 
2007). Mouse bone marrow-derived stem cells have been reported to differentiate into type 1 
pneumocytes / alveolar epithelial cells (Kotton et al. 2001) and type 2 alveolar epithelial cells 
(Krause et al. 2001). Type 1 alveolar epithelial cells and pulmonary fibroblasts have been de-
rived from circulating stem cells and progenitor cells during irradiation-induced lung injury in 
mice (Abe et al. 2004). Embryonic stem cells from mice were also shown to differentiate into 
type 2 alveolar epithelial cells (Ali et al. 2002). 
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3. Mediators of pulmonary fibrosis 
The pathogenesis of pulmonary fibrosis involves a complex network of growth factors and cy-
tokines that activate and mediate interactions between various cell types. Normally any damage 
to the lung tissue is rapidly repaired and tissue integrity and function are restored. The repair 
mechanisms however change during chronic inflammation or injury and profibrotic cytokines 
are key regulators in the formation of persistent fibrosis in IPF/UIP (Allen and Spiteri 2002).
3.1. Transforming growth factor-
Transforming growth factor-  (TGF-) exists in three mammalian isoforms, TGF-1, -2 and 
–3. TGF- is produced in an inactive form and stored at high concentrations in the ECM. The 
latent TGF--complex consists of mature TGF- bound to latency-associated protein and latent 
TGF- binding protein (LTBP) (Annes et al. 2003). LTBPs are required for the correct folding, 
secretion and localization of the TGF- complex (Hyytiäinen et al. 2004). TGF- has to be 
converted into an active form before it can bind to the receptor and be biologically effective 
(Koli et al. 2008). 
TGF- regulates tissue morphogenesis and differentiation by affecting cell proliferation, differ-
entiation, apoptosis and ECM deposition and it can have either disease-promoting or attenuat-
ing effects depending on its local concentration, activity and the cell types affected (Sheppard 
2006). TGF-1 is abundant in normal adult lung and has been shown to be increased in the 
human IPF lungs (Bergeron et al. 2003). A recent study proposed a key role for TGF-1 in 
progressive pulmonary fibrosis as a contrast to the more limited fibrosis after TGF-3 overex-
pression (Ask et al. 2008). 
TGF- acts as a chemoattractant for fibroblasts (Postlethwaite et al. 1987) and macrophages 
and stimulates them to produce other pro-inflammatory and profibrotic cytokines. TGF-1 en-
hances ECM accumulation (Eickelberg et al. 1999) and promotes fibroblast proliferation 
(Khalil et al. 2005). The alveolar epithelial cells and the fluid surrounding them include anti-
oxidants such as glutathione (Cantin et al. 1987) that protect the epithelium against harmful 
oxidants. TGF-1 however inhibits the epithelial cell synthesis of glutathione (Arsalane et al. 
1997) and induces oxidant production by myofibroblasts (Thannickal and Fanburg 1995), 
thereby increasing oxidative stress in IPF. Reactive oxygen and nitrogen intermediates have in 
turn been shown to increase TGF-1 release from cultured human alveolar epithelial cells (Bel-
locq et al. 1999). 
3.2. Bone morphogenetic proteins and gremlin
Bone morphogenetic proteins (BMPs) have been identified as negative regulators of intracellu-
lar TGF- signalling (Chen D et al. 2004). TGF- and BMPs transfer their signalling through a 
heteromeric transmembrane serine/threonine kinase complex that consist of type I and type II 
receptors. Ligand binding results in phosphorylation and activation of intracellular Smad 2/3 
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(TGF-) or Smad 1/5/8 (BMPs) that move to the nucleus where they regulate gene transcrip-
tion (Koli et al. 2008).
BMP-4 is a member of the TGF- family of growth regulatory cytokines (Chen D et al. 2004).
It is an important signalling molecule during embryonic lung development, differentiation and 
morphogenesis (Bellusci et al. 1996). BMP-4 inhibits proliferation of pulmonary fibroblasts 
and promotes their differentiation to myofibroblasts (-SMA expression) in vitro (Jeffery et al. 
2005). BMP-4-signalling is, in turn, negatively regulated by three proteins, noggin, chordin and 
gremlin (Hsu et al. 1998, Shi et al. 2001).
Gremlin or Drm (Down-regulated by v-mos) is a glycosylated protein that exists as a secreted 
and cell-associated form (Topol et al. 1997, 2000).  Gremlin upregulation has been detected in 
liver (Boers et al. 2006) and renal (Dolan et al. 2003, 2005) fibrosis. Gremlin regulates cell 
growth, differentiation, embryonic lung development and morphogenesis (Lu et al. 2001) as 
well as tumour genesis (Sneddon et al. 2006). Gremlin has also been identified as a negative 
regulator of monocyte chemotaxis which suggests a role in inflammation and immune defence 
(Chen B et al. 2004). A recent study identified gremlin as a proangiogenetic factor that pro-
motes endothelial cell migration and invasion in vitro (Stabile et al. 2007). Gremlin binds 
BMP-2, -4 and -7 and inhibits their association with their cell surface receptors and thus blocks 
subsequent BMP-mediated signalling (Hsu et al. 1998, Topol et al. 2000).
3.3. Platelet-derived growth factor
Platelet-derived growth factor (PDGF) is a potent chemoattractant and mitogen for myofibro-
blasts and it stimulates ECM production. The PDGF family consists of five disulphide-linked 
dimers (PDGF-AA, PDGF-AB, PDGF-BB, PDGF-CC, PDGF-DD) that are built from four 
polypeptide chains (PDGF-A, PDGF-B, PDGF-C and PDGF-D) (Fredriksson et al. 2004). The 
levels of several extracellular glycoproteins and matrix molecules are increased during fibrosis
and these can regulate PDGF activity. The majority of research on PDGF-mediated intracellu-
lar signalling has focused on non-pulmonary cell lines. In the lung, PDGF and its receptors ex-
ert their biological effects mainly on myofibroblasts, mediating cell proliferation, migration, 
adhesion and survival (Claesson-Welsh 1994), as well as collagen production (Yi et al. 1996). 
In particular PDGF-B is a potent mitogen and chemoattractant for rat and human fibroblasts 
and monocytes (Siegbahn et al. 1990, Osornio-Vargas et al. 1995, Sasaki et al. 2000) while
PDGF-A expression is essential for early lung development and myofibroblast function (Souza 
et al. 1995).
Alveolar macrophages from IPF patients express increased amounts of PDGF-A and PDGF-B 
mRNA and protein when compared to normal lung specimens (Nagaoka et al. 1990, Homma et 
al. 1995). Most of the PDGF released by IPF alveolar macrophages has been identified as 
PDGF-B (Nagaoka et al. 1990). PDGF-A and PDGF-B mRNA -levels have also been reported 
to be elevated in the epithelium, interstitium and macrophages of asbestos-exposed rat lungs 
(Liu et al. 1997). PDGF-C mRNA has been detected in several human tissues with the highest 
expression levels were observed in heart, pancreas and thyroid (Gilbertson et al. 2001). High 
levels of PDGF-C being found also in cultured normal human lung fibroblasts (Gilbertson et al. 
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2001). The mitogenic effect of PDGF-C on human aortic smooth muscle cells and fibroblasts 
was greater than that of PDGF-AA and similar or greater than PDGF-AB and PDGF-BB 
(Gilbertson et al. 2001). A significant increase in PDGF-C mRNA expression and a decrease in 
PDGF-D mRNA expression have been observed in the lungs of bleomycin-treated mice (Zhuo 
et al. 2004). PDGF-C was localized to areas of lung injury and fibrosis suggesting that it might 
contribute to the fibrotic response (Zhuo et al. 2004). PDGF-C over-expression during mouse
embryogenesis resulted in abnormal lung development suggesting that PDGF-C acts as a po-
tent growth factor for mesenchymal cells (Zhuo et al. 2006).
PDGF receptors
PDGF receptor (PDGFR)- and PDGFR- are receptor tyrosine kinases expressed on the sur-
face/plasma membrane of myofibroblasts. PDGF binds to the receptor subunits that are subse-
quently dimerized to form three different receptors (PDGFR-, PDGFR-, PDGFR-) that act 
in physiologically distinct signalling pathways (Bonner 2004). PDGF-AB heterodimer can di-
merize and activate the PDGFR- and PDGFR- receptors, whereas PDGF-BB is a univer-
sal ligand activating all three receptors (Bonner 2004). The most recently described PDGF iso-
forms, PDGF-C (Li et al. 2000) and PDGF-D (LaRochelle et al. 2001) can also dimerize and 
bind to the PDGFRs but require proteolytic cleavage. PDGF-CC exhibits a receptor binding 
profile similar to PDGF-AB (Gilbertson et al. 2001) while PDGF-DD binds to PDGFR-
(LaRochelle et al. 2001).
PDGFR- is induced or suppressed by a variety of factors such as interleukin (IL) -1 and 
TGF-1, whereas PDGFR- remains constitutively expressed and not affected by these stimuli 
(Bonner 2004). Experimental animal studies strongly suggest that PDGFR- and PDGFR- ac-
tivate physiologically distinct signalling pathways. Both receptors stimulate mitogenic re-
sponses, but only PDGFR- induces chemotaxis (Kang 2007). 
3.4. Peroxiredoxins and reactive oxygen species in PDGF signalling
Human lungs are constantly exposed to exogenous irritants and compounds that can cause 
damage to the lung parenchyma and alveolar epithelium. Inflammatory cells such as neutro-
phils, alveolar macrophages and eosinophils as well as alveolar epithelial cells can also pro-
duce excessive amounts of oxidants, especially when exposed to cytokines associated with in-
flammation (Kinnula and Myllärniemi 2008). Incomplete reduction of oxygen to water during 
respiration results in the formation of superoxide anions and hydrogen peroxide (H2O2), which 
can be reduced to extremely damaging hydroxyl radicals. At high levels, H2O2 is a powerful
oxidant and source of oxidative stress, but at low levels H2O2 can function as a beneficial sec-
ond messenger in signal transduction (Rhee et al. 2005). H2O2 is synthesized intracellularly in 
response to cell stimulation with growth factors and cytokines (PDGF, epidermal growth factor 
[EGF], vascular endothelial growth factor [VEGF], insulin, TGF-1, TNF-) or shear stress. 
The general model of signal transduction by the PDGF receptors consists of multiple steps. The 
receptor tyrosine kinase must be activated and phosphatase has to be inactivated in order to 
achieve effective downstream signalling after ligand-induced receptor dimerization (Bae et al. 
2000). Kinases are embedded within the intracellular domain of the PDGFRs and they are la-
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tent in the absence of stimulation, whereas phosphatases are constitutively active (Bonner 
2004). Binding of PDGF to its transmembrane receptor stimulates the production of reactive 
oxygen species (Bae et al. 2000) which then oxidize and inactivate the protein tyrosine phos-
phatases, such as phosphatase and tensin homolog deleted on chromosome 10 (PTEN) (Lee et 
al. 2002, Kwon et al. 2004). This leads to PDGFR phosphorylation and PDGF signalling. After 
the signal transduction is completed, antioxidant enzymes such as peroxiredoxins (Prx) remove 
the reactive oxygen species (Kwon et al. 2004, Choi et al. 2005), protein tyrosine phosphatase 
is activated and PDGFR becomes dephosphorylated and inactivated (Kang 2007).
Prxs are antioxidant enzymes that participate in intracellular signalling by converting H2O2 into 
H2O (Wood et al. 2003). Prx II is recruited to PDGFR after ligand-binding stimulation where it 
suppresses the oxidative inactivation of protein tyrosine phosphatase by removing H2O2 thus 
acting as a negative regulator of PDGF signalling (Choi et al. 2005). Prx II deficiency in turn 
results in increased production of H2O2, enhanced activation of PDGFR and increased cell pro-
liferation and migration in response to PDGF (Choi et al. 2005). 
PTEN is a tumour suppressor that inhibits cell proliferation and migration and induces apopto-
sis (Yamada and Araki 2001). TGF- downregulates PTEN expression whereas overexpression 
of PTEN inhibits the effects of TGF- (Kuwano 2006). PTEN expression is decreased in IPF 
myofibroblasts which may contribute to the pathogenesis of pulmonary fibrosis (Kuwano 
2006, White et al. 2006). H2O2 has been shown to oxidize and inactivate PTEN reversibly (Lee 
et al. 2002).  This implies that the H2O2 produced under pathologic conditions may increase cell 
proliferation and lead evokes hyperplasia and tumourogenesis by inhibiting PTEN function 
(Lee et al. 2002). Differentiated alveolar macrophages produce increased amounts of reactive 
oxygen species, which leads to PTEN deficiency and prolonged survival of alveolar macro-
phages (Flaherty et al. 2006).
3.5. Matrix metalloproteinases 
Matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases are pro-
teolytic enzymes, which are involved in cell-cell signalling events. They participate in pulmo-
nary development and adult lung homeostasis, but an imbalance in their expression may be in-
volved in the  tissue destruction seen in lung inflammation and pulmonary fibrosis (Pardo and 
Selman 2006). Gene expression analyses have revealed increased expression of the proinflam-
matory MMP-7, also known as matrilysin, in IPF (Cosgrove et al. 2002, Zuo et al. 2002, Kelly 
et al. 2006, Selman et al. 2006) and NSIP lungs (Cosgrove et al. 2002). MMP-7 has been local-
ized to the alveolar epithelium and it is believed to play a role in re-epithelialization 
(Dunsmore et al. 1998) and EMT induction (McGuire et al. 2003). 
4. Experimental animal models of pulmonary fibrosis 
Bleomycin is an antibiotic that is effective against squamous cell carcinomas and skin tumours, 
but it can also have toxic effects resulting in lung fibrosis (Moore and Hogaboam 2008). 
Bleomycin-induced pulmonary fibrosis is a well-characterized and widely used animal model, 
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although its actual relevance has been debated (Gauldie and Kolb 2008, Moeller et al. 2008). 
Bleomycin administration to experimental animals results in epithelial injury, followed by in-
flammatory infiltrates and collagen accumulation (Moore and Hogaboam 2008). However, 
some reports have demonstrated that intratracheal administration of bleomycin has a resolving 
nature that does not resemble human pulmonary fibrosis. The fibrotic response of experimental 
animals, e.g. mice, to bleomycin is also strain-dependent (Moore and Hogaboam 2008). A 
summary of therapeutic agents used to attenuate and/or prevent the development of bleomycin-
induced pulmonary fibrosis is presented in Table 2.
Asbestosis is a fibrotic interstitial lung disease that has many similarities with IPF, including 
the occurrence of UIP histopathology (Manning et al. 2002). In addition, comparison of thin-
section computed tomography features of asbestosis and IPF has shown that the pattern of as-
bestosis closely resemble biopsy-proven UIP (Copley et al. 2003). A recently developed mouse 
model of asbestos-induced progressive fibrosis has been shown to reproduce human IPF/UIP –
like lesions (Tan et al. 2006).
Irradiation-induced fibrosis is clinically relevant but it takes over 30 weeks to develop making 
it an expensive choice (Moore and Hogaboam 2008). Silica induces persistent fibrotic lesions 
that resemble those of humans exposed to occupational dusts. However, silica-induced fibrosis 
also takes several weeks to develop and is mouse strain-specific (Moore and Hogaboam 2008).  
The use of transgenic mice permits the study of a particular molecule. Gene expression can be 
regulated and induced in appropriately aged mice. Viral vectors (adenovirus, lentivirus) can be 
used to deliver mediators of fibrosis or antifibrotic agents to the experimental animals (Gauldie 
and Kolb 2008, Moore and Hogaboam 2008).
Fluorescein isothiocyanate (FITC) induces persistent fibrosis that lasts for at least six months. 
The use of FITC allows visualization of fibrosis progression at the areas of FITC deposition 
because of its green fluorescence. FITC-induced pulmonary fibrosis can also be demonstrated 
in various mice strains. Although there are many advantages, the major disadvantage of the use 
of FITC is that it is not a clinically relevant model (Moore and Hogaboam 2008).
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Table 2. Experimental animal models used to attenuate and/or prevent the development of pulmonary fibrosis. All 
trials have used mice and bleomycin-induced pulmonary fibrosis unless stated otherwise. 
Agent Target Mechanisms of action Reference
Anti-TNF-
antibody
TNF- Prevents collagen deposition and alveo-
lar damage 
Piguet et al. 1989
Soluble TNF 
receptor
TNF- Reduces lung collagen content in bleo-
mycin- and silica-induced pulmonary 
fibrosis 
Piguet and Vesin 1994
TNF- receptor 
knock-out mice
TNF- receptor Reduces TGF-  and PDGF gene ex-
pression in asbestos-induced pulmonary 
fibrosis
Liu et al. 1998
Overexpression 
of TNF-
Collagen pro-
duction
Protects from bleomycin- and TGF--
induced pulmonary fibrosis
Fujita et al. 2003
Pirfenidone TNF- Suppresses TNF- production and 
increases anti-inflammatory IL-10
Nakazato et al. 2002
Anti-v6 
integrin anti-
bodies
TGF- Prevents TGF- activation and radia-
tion-induced pulmonary fibrosis
Puthawala et al. 2008
Inhibitor to 
TGF- receptor 
I
TGF- Inhibits binding of TGF- to its recep-
tor, attenuates the progression of pul-
monary fibrosis in rats
Bonniaud et al. 2005
-Acetyl-L-
cysteine
TGF-1 and 
TGF-1 receptor
Inhibits TGF-1-mediated signalling in 
cultured hepatic stellate cells
Meurer et al. 2005
IFN- TGF- Reduces TGF-, collagen I and collagen 
III mRNA
Gurujeyalakshmi and Giri 
1995
Decorin TGF- Binds and inhibits TGF- activation Kolb et al. 2001
BMP-7 Gremlin overex-
pression
Reduces asbestos-induced collagen 
deposition and neutrophil accumulation
Reverses mouse kidney fibrosis and 
TGF-1-induced EMT
Myllärniemi et al. 2008
Zeisberg et al. 2003, 2005
Imatinib mesy-
late
PDGFR, c-Kit, 
Abl
Reduces bleomycin- and asbestos-
induced pulmonary fibrosis
Anti-inflammatory
Daniels et al. 2004, Aono et 
al. 2005, Abdollahi et al. 
2005
Chaudhary et al. 2006
Gefitinib EGF Inhibits EGFR-mediated signalling
Augments fibrosis by reducing epithe-
lial proliferation and regeneration
Rice et al. 1999, Ishii et al. 
2006
Suzuki et al. 2003
Recombinant 
human HGF
Epithelial cells Induces migration, reduces collagen 
deposition
Dohi et al. 2000
BIBF 1000 Inhibitor of the 
PDGF, VEGF 
and FGF recep-
tors
Attenuates fibrosis in rats, inhibits 
myofibroblast differentiation in vitro
Chaudhary et al. 2007
Soluble VEGF 
receptor
VEGF Attenuates apoptosis, decreases the 
number of inflammatory cells in BAL 
fluid
Hamada et al. 2005
Antibody to 
CXCL12
Circulating fi-
brocytes
Reduces fibrocyte recruitment to the 
sites of lung injury
Phillips et al. 2004
Nrf2 Antioxidant 
pathways
Nrf2 knock-out mice more susceptible 
to bleomycin-induced lung injury
Cho et al. 2004
Inhibitors of 
caspases
Epithelial cell 
and fibroblast 
apoptosis
Inhibits bleomycin-induced apoptosis 
and fibrosis
Wang et al. 2000b
Batimastat MMPs Inhibits MMP-mediated signalling and 
tissue remodelling
Corbel et al. 2001
24
4.1. Inhibition of profibrotic signalling
4.1.1. Tumour necrosis factor-
Anti-TNF- antibody has been shown to attenuate bleomycin-induced pulmonary fibrosis 
(Piguet et al. 1989) and treatment with soluble TNF receptor has prevented the development of 
bleomycin- and silica- induced pulmonary fibrosis and attenuated established fibrosis in mice 
(Piguet and Vesin 1994). TNF- receptor knock-out mice were protected against asbestos-
induced pulmonary fibrosis (Liu et al. 1998). Although overexpression of TNF- has been as-
sociated with increased inflammation and lung fibrosis in animal models (Ortiz et al. 1998), 
TNF- can also provide protection against bleomycin-induced lung inflammation and injury in 
TNF- deficient mice (Kuroki et al. 2003). This is supported by the finding that mice overex-
pressing TNF- were protected from bleomycin- and TGF--induced pulmonary fibrosis (Fu-
jita et al. 2003). Pirfenidone (5-methyl-1-phenyl-2(1H)-pyridone) administration suppressed 
TNF- production and increased the levels of the anti-inflammatory cytokine, IL-10, in mice 
(Nakazato et al. 2002). 
4.1.2. Transforming growth factor-
Since there is considerable evidence for a role for TGF- in the pathogenesis of IPF, therapeu-
tic approaches targeting TGF- signalling could prove beneficial. Compounds that affect TGF-
 activation and signalling include anti-v6 integrin antibodies. The epithelial v6-integrin 
is upregulated in pulmonary fibrosis and it participates in the activation of latent TGF-
(Munger et al. 1999). Anti-v6 integrin antibodies have been used to prevent TGF- activa-
tion and radiation-induced pulmonary fibrosis in mice (Puthawala et al. 2008). 
Binding of active TGF- to its receptor TGF-RI or activin-like kinase receptor-5 (ALK-5) ac-
tivates downstream signalling events mediated by the intracellular Smad family molecules. In-
hibition of this binding by an orally active ALK-5 kinase inhibitor has been shown to attenuate 
the progression of pulmonary fibrosis in rats overexpressing TGF-1 (Bonniaud et al. 2005). 
Reactive oxygen species have also been associated with the activation of latent TGF- (Barcel-
los-Hoff and Dix 1996). -Acetyl-L-cysteine (NAC) can act as an antioxidant against harmful 
oxidative agents. NAC has been shown to inhibit TGF-1 and TGF-1 receptor function as 
well as TGF-1-mediated signalling in cultured hepatic stellate cells (Meurer et al. 2005). This 
inhibition was speculated to be due to breakage of disulfide bonds and changes in the redox 
status of cysteine residues in the receptor (Meurer et al. 2005).
Daily treatment with interferon (IFN)- after bleomycin-induced fibrosis in mice has resulted 
in a reduction in TGF-, collagen I and collagen III mRNA levels (Gurujeyalakshmi and Giri
1995). IFN- has also been shown to reduce TGF-2 expression in human bronchial epithelial 
cells by regulating the intracellular inhibitory TGF- signalling transducer, Smad7 (Wen et al. 
2004).
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4.1.3. Bone morphogenetic proteins
The balance between TGF- and BMP-signalling seems to be an important regulator of fibro-
genesis and novel therapeutic strategies inhibiting TGF- and/or enhancing BMP signalling are 
being sought. BMP-signalling was impaired and its target gene expression reduced due to 
upregulated gremlin in asbestos-induced pulmonary fibrosis in mice (Myllärniemi et al. 2008). 
BMP-7 treatment reduced asbestos-induced fibrosis, collagen deposition and neutrophil accu-
mulation (Myllärniemi et al. 2008). Experimentally induced mouse kidney fibrosis and TGF-
1-induced EMT could be reversed by administration of recombinant human BMP-7, evidence 
of a potential therapeutic role for gremlin inhibition (Zeisberg et al. 2003, 2005). This protein
also enhanced hepatocyte proliferation and liver regeneration in mice after partial liver tissue 
resection (Sugimoto et al. 2007) suggesting BMPs may actually have a fibroprotective role.
4.1.4. Platelet-derived growth factor
Due to the crucial role of PDGF signalling in fibrogenesis, novel treatments are aimed at the 
inhibition of PDGF receptor tyrosine kinases. Imatinib mesylate, also known as Gleevec 
(STI571, Novartis Pharmaceuticals Corp.) or Glivec, is a tyrosine kinase inhibitor with activity 
against c-Abl and c-kit (Druker et al. 1996) and PDGFR (Buchdunger et al. 1996, 2000). Since 
both PDGF (Liu et al. 1997) and c-Abl (Daniels et al. 2004) have been associated with pulmo-
nary fibrosis, imatinib mesylate may possess potential in limiting myofibroblast proliferation 
and may be useful in treating pulmonary fibrosis. In addition to PDGFR-mediated signalling, 
imatinib mesylate can also inhibit Smad2/3-independent signalling pathways downstream of 
TGF- by targeting c-Abl, and thus it can block TGF--induced profibrotic events (Daniels et 
al. 2004). 
In experimental animal models, imatinib mesylate reduced bleomycin- (Daniels et al. 2004, 
Aono et al. 2005) and asbestos-induced (Abdollahi et al. 2005) fibroblast proliferation and 
pulmonary fibrosis in mice. Imatinib mesylate has also been reported to have anti-
inflammatory effects against bleomycin-induced pulmonary fibrosis (Chaudhary et al. 2006). A 
recent study demonstrated that imatinib mesylate inhibited PDGFR- activation as well as 
pulmonary fibroblast and epithelial cell proliferation, but did not affect the differentiated myo-
fibroblast phenotype or EMT (Vittal et al. 2007).  Imatinib mesylate administration in the later 
stages of bleomycin-induced pulmonary fibrosis did not have any significant antifibrotic ef-
fects (Vittal et al. 2007). Similar results have been obtained in liver fibrosis where oral imatinib 
mesylate reduced early fibrogenesis but failed to have an antifibrotic effect in the later stages 
of the disease (Neef et al. 2006). 
4.1.5. Other growth factors
Gefitinib (Iressa, Astra Zeneca) is an anticancer drug that binds to EGF receptors and in that 
way blocks the attachment of EGF to its receptor and the subsequent activation of the intracel-
lular tyrosine kinase. Treatment with gefitinib has however provided contradictory results. In-
hibition of EGFR-mediated signalling could prevent bleomycin-induced pulmonary fibrosis in 
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mice (Rice et al. 1999, Ishii et al. 2006), but it also augmented bleomycin-induced fibrosis by 
reducing epithelial proliferation and regeneration (Suzuki et al. 2003).  
Hepatocyte growth factor (HGF) regulates the growth of the lung epithelium during lung injury 
and subsequent fibrogenesis (Ware and Matthay 2002). HGF induces the migration of epithe-
lial cells and inhibits the apoptosis of alveolar and bronchial cells (Ware and Matthay 2002). 
Gene transfer of HGF reduced bleomycin-induced pulmonary fibrosis (Gazdhar et al. 2007) 
and administration of recombinant human HGF has been shown to attenuate bleomycin-
induced pulmonary fibrosis and collagen deposition in experimental animal models (Dohi et al. 
2000). Since HGF has both fibrinolytic and antiapoptotic effects, it might represent a potential 
therapeutic agent for patients with pulmonary fibrosis.
A recent study examined the antifibrotic effects of BIBF 1000, a small molecule inhibitor of 
the tyrosine kinase receptors of PDGF, VEGF and FGF, in a rat model of bleomycin-induced 
pulmonary fibrosis (Chaudhary et al. 2007). Treatment with BIBF 1000 attenuated fibrosis in 
vivo and inhibited myofibroblast differentiation in vitro. This implies that a combined inhibi-
tion of several profibrotic growth factors might be beneficial in controlling pulmonary fibrosis 
(Chaudhary et al. 2007). Gene transfection of a soluble VEGF receptor to mice with bleomy-
cin-induced pulmonary fibrosis attenuated fibrosis and apoptosis and decreased the number of 
inflammatory cells in the BAL fluid (Hamada et al. 2005).
The CXC chemokines are small chemotactic cytokines that act as chemoattractants for circulat-
ing fibrocytes. They also participate in angiogenesis, cell differentiation and inflammation 
(Strieter et al. 2007). The expression of the fibrocyte chemoattractant, CXCL12, as well as the 
number of circulating fibrocytes is enhanced in the peripheral blood of patients with IPF (Me-
hrad et al. 2007). CXCL12 and its corresponding receptor CXCR4 are also upregulated in fi-
broblasts in the lungs of mice with bleomycin-induced fibrosis (Phillips et al. 2004). Increased 
amounts of chemokines recruit fibrocytes to the sites of lung injury and antibodies to CXCL12 
have been shown to reduce fibrocyte recruitment and to attenuate bleomycin-induced fibrosis 
(Phillips et al. 2004). 
4.2. Antioxidative agents
NF-E2-related factor 2 (Nrf2) is a transcriptional factor regulating antioxidant response ele-
ment-mediated induction of antioxidants. Nrf2 knock-out mice were more susceptible to bleo-
mycin-induced lung injury and fibrogenesis than wild-type control mice, suggesting a protec-
tive role for the Nrf2-mediated antioxidant pathways (Cho et al. 2004). The cellular redox im-
balance and oxidative stress can lead to the release of Nrf2, followed by Nrf2 binding to the 
antioxidant response element, and induction of antioxidant transcription (Walters et al. 2008). 
Various antioxidative enzymes (superoxide dismutases, glutathione, lactoferrin, transferrin, 
glutaredoxin and thioredoxin) protect the airway epithelium from oxidative stress and most of 
them are regulated by Nrf-2 (Walters et al. 2008). Several new synthetic antioxidants have 
been developed and tested in experimental animal models of oxidant-mediated lung injury, but 
the effects of these agents still need to be assessed in human IPF (Day 2008).
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5. Treatment strategies for idiopathic pulmonary fibrosis
5.1. Current treatment strategies
Current treatment options for IPF are limited and frequently unsuccessful (Bouros and Antoniu 
2005, Gharaee-Kermani et al. 2007). Due to the progressive nature of the disease, lung trans-
plantation remains the best hope of intervention and long-term survival. Approximately 40% of
IPF patients are alive five years after the transplantation (Thabut et al. 2003). 
IPF is treated with anti-inflammatory and immunosuppressive drugs, such as corticosteroids 
(prednisolone) and azathioprine (ATS/ERS 2000) (Table 3). Corticosteroids suppress neutro-
phil and lymphocyte migration into the lung and decrease the amount of immune complexes. 
Although corticosteroids are widely used, there is no clear evidence for any survival benefit 
and high-dosage of the compounds can cause side-effects and toxicity (Flaherty et al. 2001b). 
Current recommendations for the treatment of IPF include prednisolone with a starting dosage 
0.5 mg/kg/day for four weeks, after which the dosage is reduced. Azathioprine is recom-
mended at 2-3 mg/kg/day, and concurrent treatment with both prednisolone and azathioprine 
has also been used (Raghu et al. 1991). These compounds have however numerous side-effects 
and if no response is achieved during 3-6 months, then treatment should not be continued. 
Table 3. Therapeutic agents used in clinical trials in IPF. (Modified from Gharaee-Kermani et al. 2007). 
Agent Target Mechanisms of action Reference
Anti-CTGF anti-
body
CTGF Inhibits CTGF Mageto et al. 2004
Azathioprine Immune suppres-
sion
Inhibits cell proliferation Raghu et al 1991, 
ATS/ERS 2000
Bosentan Endothelial cell, 
endothelin-1
Anti-angiogenic King et al. 2008
Colchicine Fibrosis Reduces TGF-1 expression Tzortzaki et al. 2007
Corticosteroids Inflammation Suppress neutrophil and lympho-
cyte action
Flaherty et al. 2001b
Cyclophosphamide Inflammation Suppresses lymphocyte action Kondoh et al. 2005
Etanercept TNF- Inhibits TNF- Niden et al. 2002
Imatinib mesylate PDGF Inhibits PDGFR, c-Kit, Abl Buchdunger et al. 2002
IFN-1b Fibroblast, macro-
phage
Inhibits cell proliferation Raghu et al. 2004
NAC Oxidative stress Antioxidant, increases tolerance 
to oxidative stress
Demedts et al. 2005
Pirfenidone Fibrosis Inhibits TGF-, PDGF Raghu et al. 1999, Azuma 
et al. 2005
Warfarin Coagulation Anticoagulant Kubo et al. 2005
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5.2. Human trials on new treatment modalities
Cyclophosphamide is an immunomodulatory agent that suppresses lymphocyte functions. A 
number of trials have indicated variable benefits from cyclophosphamide and it may be more 
efficient in patients with other interstitial lung diseases (Kondoh et al. 2005).
IFN--1b has both anti-inflammatory and anti-fibrotic effects and it regulates macrophage and 
fibroblast function (Bouros and Antoniu 2005). In a randomized, placebo-controlled trial IFN-
-1b was administered to IPF patients who were unresponsive to corticosteroid therapy. IFN--
1b had no effect on pulmonary function, survival or the quality of life (Raghu et al. 2004). 
IFN--1b has also been used together with prednisolone (Ziesche et al. 1999) to inhibit fibro-
genesis, but without significant impact on disease progression. Although IFN--1b downregu-
lates TGF-1, treatment with IFN--1b had no effect on TGF-1 expression in patients with 
IPF, but treatment with colchicine reduced TGF-1 expression (Tzortzaki et al. 2007). IFN-1b
can also modulate the imbalance between the Th1 (IL-2, -12, -18, IFN-) and Th2 (IL-4, -5, -
10, -13) cytokines in the lungs of IPF patients and it can suppress fibroblast activation (Ziesche 
et al. 1999). 
The oxidant/antioxidant imbalance in the IPF lungs is associated with reduced levels of glu-
tathione (Kinnula and Myllärniemi 2008). Some thiol-related compounds, such as glutathione 
derivatives, cysteine, NAC and lipoic acid have been proposed to be used in disease prevention 
and treatment since increased thiol levels have been associated with increased tolerance to oxi-
dative stress. NAC is a synthetic precursor of the intracellular antioxidant glutathione and ad-
ministration of NAC in combination with azathioprine and prednisone has been shown to slow 
the deterioration in lung function tests (Demedts et al. 2005).  
Bosentan is an anti-angiogenetic compound, blocking the actions of the profibrotic peptide, 
endothelin-1 and it is already used to treat human pulmonary arterial hypertension (Dupuis and 
Hoeper 2008). Endothelin-1 is expressed by epithelial cells and it is upregulated in IPF (Uguc-
cioni et al. 1995). Bosentan has demonstrated protective effects against bleomycin-induced 
pulmonary fibrosis in rats (Park et al. 1997) and it has been evaluated for human use in a ran-
domized placebo-controlled multicenter study (King et al. 2008). Although no significant bene-
fits were observed in bosentan-treated IPF patients, an IPF patient subgroup that was diagnosed 
with surgical biopsy did show a delayed disease progression and increased survival (King et al. 
2008).
Inhibition of profibrotic cytokine signalling in humans
Preliminary studies on the use of etanercept, a recombinant inhibitor of the TNF- receptor, 
have shown improved pulmonary functions in IPF patients (Niden et al. 2002). 
Imatinib mesylate is a tyrosine kinase inhibitor aimed against c-Abl, c-kit and PDGFR (Druker 
et al. 1996) and it is already in use for the treatment of chronic myeloid leukaemia (Druker et 
al. 2001) and gastrointestinal tumours (Verweij et al. 2003). However, there are an increasing 
number of reports about the adverse effects of imatinib mesylate treatment since patients with 
chronic myeloid leukaemia or gastrointestinal tumours have developed interstitial pneumonia 
when treated with 400 mg/day oral imatinib mesylate (Isshiki et al. 2004, Ohnishi et al. 2006). 
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A phase II/III clinical study of the effects of orally administered imatinib mesylate in IPF pa-
tients has been completed but the results remain to be published. 
Connective tissue growth factor (CTGF) is a downstream mediator of TGF- that stimulates 
collagen and fibronectin production and myofibroblast differentiation (Leask and Abraham 
2003). The expression of CTGF mRNA has been shown to be increased in the BAL cells of pa-
tients with IPF (Allen et al. 1999). In a phase I clinical trial, a neutralizing antibody against 
CTGF was found to be both safe and well tolerated (Mageto et al. 2004).
5.3. Potential treatment strategies
Angiogenesis is the process where new blood vessels are formed from pre-existing ones 
(Tzouvelekis et al. 2006). Angiogenesis plays a key role in inflammation, wound healing and 
tumour growth and increased angiogenetic activity (Keane et al. 1997) and varying degrees of 
blood vessel growth have been demonstrated in the IPF lung (Ebina et al 2004).  Inducers of 
angiogenesis include VEGF and FGF (Tzouvelekis et al. 2006). Therapy aimed at inhibition of 
the angiogenic chemokines (IL-8) or enhancement of angiostatic chemokines (CXCL10) might 
represent a new treatment option for IPF. 
Increased procoagulant activity is characteristic of IPF and thrombin inhibition has been used 
to block collagen accumulation in bleomycin-induced pulmonary fibrosis in mice (Howell et 
al. 2001). Coagulation factors can transmit their effects through the activation of proteinase-
activated receptors (PAR). PAR-1 is a transmembrane receptor of the proinflammatory and 
profibrotic protease, thrombin (Howell et al. 2002). PAR-1 has been identified as a novel target 
for antiangiogenetic agents in many tumour types. PAR expression is increased in IPF (Howell 
et al. 2002) and its activation increases the expressions of PDGF, CTGF and collagen expres-
sion and it stimulates myofibroblast differentiation (Blanc-Brude et al. 2005). Thus activation 
of the coagulation system during fibrogenesis may be linked to other profibrotic mechanisms 
and thus the development of PAR1 receptor antagonists could prove beneficial in treating IPF 
(Howell et al. 2002).
Reduced mortality has been observed in IPF patients treated with anticoagulant agents (war-
farin or dalteparin) and prednisone (Kubo et al. 2005). In a prospective randomized study, IPF-
patients treated with anticoagulants and prednisolone exhibited better survival when compared 
to patients receiving prednisolone alone (Kubo et al. 2005).
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AIMS OF THE STUDY
The present study attempted to find novel diagnostic markers and potential treatment options 
for IPF. 
The levels of MMP-7 were investigated in the BAL fluid in order to assess whether they could 
be used in the differential diagnostics of idiopathic interstitial lung diseases, especially in the 
differentiation of IPF from other interstitial lung disorders
Gremlin and BMP-4 expression levels in normal and IPF lungs were compared and the local-
ization and expression of gremlin and BMP-4 examinedto determine if they could be used in 
the differential diagnosis or in the assessment of disease severity of IPF/UIP and NSIP
The expression and localization of the PDGF receptors and Prx II were investigated and cell 
proliferation and nitrosative/oxidative stress in normal and IPF lungs was assessed
The effects of imatinib mesylate on fibrogenesis in asbestos-induced pulmonary fibrosis of 
mice and primary human pulmonary fibroblast migration were studied to evaluate whether it 
could attenuate pulmonary fibrosis 
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MATERIALS AND METHODS
1. Antibodies 
Primary antibodies used in immunostaining of tissue sections were anti-human MMP-7 anti-
human gremlin, anti-human BMP-4, anti-human -smooth muscle actin (-SMA), anti-Prx II, 
anti-PDGFR, anti-PDGFR, anti-Ki67 and anti-nitrotyrosine antibody (Table 4). Primary an-
tibodies used in the immunoblotting studies were Smad1, P-Smad1, anti-Prx II antibody and 
anti-peroxiredoxin-SO3 (Table 4).
Primary human IPF fibroblasts obtained from explanted lung tissue were seeded on glass slides 
and characterized as myofibroblasts by positive immunocytochemical staining with anti--
SMA and by negative staining with mouse monoclonal anti-CD45 common leukocyte antigen 
antibody. Only sporadic cells stained positive with mouse monoclonal anti-desmin (muscle cell 
marker) and mouse monoclonal anti-keratin (epithelial cell marker) (all antibodies from Neo-
markers). 
The fibroblast slides were used in immunofluorescence studies and treated with rabbit poly-
clonal anti-PDGF receptor , anti-PDGF receptor , anti-c-Abl or anti-c-Kit (Table 4). Anti-
body binding was detected using either anti-rabbit or anti-mouse fluorescein conjugated secon-
dary antibodies (both from Chemicon). Cell nuclei were visualized with 4’,6-diamino-2-
phenylindole (Invitrogen, Paisley, UK).
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Table 4. Antibodies used in the studies. 
IC = Immunocytochemistry, IF = immunofluorescence, IHC = immunohistochemistry, WB = western blotting
Antibody Source Studies Manufacturer
-smooth muscle 
actin (SMA)
Mouse monoclonal IHC (II, III), IC (II, III, V) Neo Markers, Inc. 
Fremont, CA, USA
BMP-4 Mouse monoclonal IHC (II, III) Chemicon, Hampshire, 
UK
c-Abl Mouse monoclonal IF (V) Lab Vision, Fremont, CA, 
USA
c-Kit Mouse monoclonal IF (V) Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, 
USA
Cytokeratin Mouse monoclonal IC (II, III, V) Neo Markers
Desmin Mouse monoclonal IC (II, III, V) Neo Markers
Gremlin Goat polyclonal IHC (II, III) Santa Cruz Biotechnol-
ogy
Ki67 Rabbit polyclonal IHC (IV) Thermo Scientific, 
Fremont, CA, USA
MMP-7 Mouse monoclonal IHC (I) R&D Systems Europe 
Ltd, Abington, UK
Nitrotyrosine Rabbit polyclonal IHC (IV) Upstate, Lake Placid, NY, 
USA
PDGFR- Rabbit polyclonal IHC (IV), IF (V) Cell Signaling Technol-
ogy, Danvers, MA, USA
PDGFR- Rabbit polyclonal IHC (IV), IF (V) Cell Signaling Technol-
ogy
Prx II Rabbit polyclonal IHC, WB (IV) LabFrontier, Seoul, Korea
Prx-SO3 Rabbit polyclonal WB (IV) LabFrontier
P-Smad1 Rabbit polyclonal WB (II) Dr. Peter ten Dijke, The 
Netherlands Cancer
institute, Amsterdam, 
Netherlands
Smad1 Mouse monoclonal WB (II) Santa Cruz Biotechnol-
ogy
2. Tissue sample studies (I, II, III, IV)
All patients received written information and provided their permission to use the samples. The 
Ethics Committees of the Helsinki and Tampere University Central Hospitals approved the 
studies. The use of the clinical material has been registered at www.hus.fi/clinicaltrials.
IPF/UIP and NSIP and were diagnosed according to the diagnostic criteria set by American 
Thoracic Society and European Respiratory Society (ATS/ERS 2000) on the basis of the char-
acteristic clinical and/or radiological findings, and/or by histology and by the exclusion of
other diseases (Table 5). Lung function parameter tests included flow volume spirometry and 
single breath diffusion capacity.
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Table 5. Patient material for the immunohistochemical studies. IPF/UIP biopsies were either diagnostic (named 
IPF/UIP early) or obtained from lung explants taken during lung transplantation (IPF/UIP advanced). All NSIP –
biopsies were taken at the time of diagnosis either during open lung surgery or thoracoscopy. Control biopsies 
were obtained from healthy lung derived from operations where benign tumours were removed or from unused 
donor lung tissue obtained during lung transplantation. 
Study I Study II Study III Study IV
Control 3 10 - 10
IPF/UIP
  IPF/UIP early
  IPF/UIP advanced
7 10
19
  5
10
NSIP 6 - 12 -
Sarcoidosis 3 - - -
2.1. Immunohistochemistry
Paraffin embedded tissue samples were deparaffinized in xylene and rehydrated in graded al-
cohol. Antigens were retrieved by heating the sections in 10 mM citrate buffer (pH 6.0) for 10 
minutes. Endogenous peroxidase activity was blocked with 0.3% hydrogen peroxidase. For 
immunostaining, Vectastain Elite ABC Goat IgG kit (Vector Laboratories, Burlingame, CA, 
USA) or Zymed ABC Histostain-Plus kit (Zymed, San Francisco, CA, USA) was used accord-
ing to the manufacturer’s protocol.  Detection was performed with biotinylated anti-goat or 
anti-mouse secondary antibody, horseradish peroxidase complex and 3-amino-9 ethyl-
carbazole chromogen (Zymed). The sections were counterstained with Mayer’s haematoxylin 
and mounted on glass slides. Control sections were treated with goat IgG (Jackson ImmunoRe-
search Laboratories, West Grove, PA, USA) or mouse isotype control (Zymed) to determine 
the specificity of the staining.
Double staining was performed with Vectastain Elite ABC Mouse IgG and Goat IgG kits (Vec-
tor Laboratories) according to the manufacturer’s protocols (Study III). A blocking step with 
an avidin/biotin blocking kit (Vector Laboratories) was performed prior to the addition of the 
secondary antibody. -SMA was detected with 3,3´-diaminobenzidine (DAB) substrate kit for 
peroxidase (Vector Laboratories), with added nickel chloride producing a black reaction prod-
uct. Gremlin was visualized with Vector® NovaRed™ substrate kit (Vector Laboratories) pro-
ducing a vred reaction product. The sections were counterstained briefly with Mayer’s haema-
toxylin and mounted in non-aqueous mounting media (Vector Laboratories).
Morphometrical analysis of gremlin, -SMA, Prx II, PDGFR, PDGFR, Ki67 and nitroty-
rosine immunoreactivity was performed using Image-Pro Plus 6.1. (Media Cybernetics, Inc, 
Silver Spring, MD, USA) software. Three randomly chosen images from the lung parenchyma 
of each stained section were taken. If the area in the microscope field did not contain >50% tis-
sue, the slide was moved vertically until a representative area was seen. The areas of positive 
and negative staining were evaluated with Image-Pro Plus 6.1. BMP-4 staining was quantitated 
by counting individual 300 cells/section and evaluating the amounts of BMP-4 positive and 
negative cells.
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2.2. Real-time RT-PCR (Studies II, III) 
 
For quantitative real-time reverse transcriptase polymerase chain reaction (RT-PCR) analyses, 
total RNA was extracted from snap-frozen lung biopsies (Table 6) by mechanical 
homogenization and Phase Lock Gel Heavy kit according to the manufacturer´s (Eppendorf, 
Hamburg, Germany) instructions. Reverse transcription was carried out with Random hexamer 
primers (Invitrogen) and Superscript II reverse transcriptase (Life Technologies, Gaithersburg, 
MD, USA) using 1.0 μg of total RNA according to manufacturer's instructions. The cDNAs 
were amplified using TaqMan Assays-on-Demand gene expression products (Applied 
Biosystems, Foster City, CA, USA) and GeneAmp 5700 Sequence Detector thermal cycler 
(Applied Biosystems). Control amplifications directly from RNA were performed in order to 
rule out DNA contamination. The results have been expressed as mRNA expression levels 
normalized to the levels of a gene with constant expression (actin). 
 
Table 6. Patient characteristics for the real-time RT-PCR studies. IPF/UIP biopsies were either diagnostic (named 
IPF/UIP early) or obtained from lung explants taken during lung transplantation (IPF/UIP advanced). All NSIP –
biopsies were taken at the time of diagnosis either during open lung surgery or thoracoscopy. Control biopsies 
were obtained from healthy lung derived from operations where benign tumours were removed or from unused 
donor lung tissue obtained during lung transplantation.  
 
 Study II Study III 
Control 6 7 
IPF/UIP 
  IPF/UIP early 
  IPF/UIP advanced 
6 - 
6 
4 
NSIP - 6 
 
 
2.3. Western blot (Studies II, IV) 
 
Tissue biopsies were homogenized in phosphate-buffered saline (PBS) and 50 μg of protein 
was used in standard reducing or non-reducing SDS-PAGE and blotted into membranes. The 
membranes were stained with 0.2% Ponceau S (Sigma-Aldrich Co., St. Louis, MO, USA) in 
1% acetic acid to ensure equal loading of proteins. Membranes were probed with anti-Prx II or 
anti-peroxiredoxin-SO3 antibodies, followed by anti-rabbit secondary antibody treatment 
(Table 4). An enhanced chemiluminesence system (Amersham Pharmacia Biotech Europe 
GmbH, Freiburg, Germany) or Odyssey Infrared Imaging System (LiCor Biotechology, 
Lincoln, Nebraska, USA) was used for detection. 
 
 
2.4. Two-dimensional gel electrophoresis and protein identification (Study IV) 
 
IPF/UIP (n = 4) and control (n = 4) lung tissue samples were powdered as frozen and further 
purified by acetone precipitation in order to determine the oxidation state of the catalytic 
cysteines in Prx II. The protein extract was resuspended in urea buffer (7 M urea, 2 M thiourea, 
4% [w/v] CHAPS, 0.15% [w/v] DTT, 0.5% [v/v] carrier ampholytes 3-10, Complete Mini 
protease inhibitor cocktail [Roche, Basel, Switzerland]), disrupted and centrifuged. The protein 
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solution was adjusted with urea buffer to a final volume of 350 l and in-gel rehydration was 
performed overnight. Isoelectric focusing was carried out in IPG strips (pH 4-7, 18 cm, GE 
Healthcare) with the Multiphor II system (GE Healthcare, Buckinghamshire, UK) under 
paraffin oil at 55 kWh. SDS-PAGE was performed overnight in polyacrylamide gels (12.5% T, 
2.6% C) with the Ettan DALT II system (GE Healthcare) at 1-2 W per gel and 12ºC. The gels 
were silver stained, analysed with the 2-D PAGE image analysis software Melanie 3.0 
(GeneBio, Geneva, Switzerland) and reproducible changes in spot intensity (at least 2-fold) 
were marked in the gel.  
 
Excised spots in gel were digested to achieve protein identification. Peptide masses were 
measured with a VOYAGER-DETM STR (Applied Biosystems, Foster City, CA, USA), and 
proteins identified with the ProFound database version 2005.02.14 
(http://prowl.rockefeller.edu/prowl-cgi/profound.exe) and the following parameters (20 ppm; 1 
missed cut; MH+; +C2H2O2@C [Complete], +O@M [Partial]). A detailed analysis of cysteine 
oxidation within the detected peptides was conducted with PeptideMass 
(http://au.expasy.org/tools/peptide-mass.html).    
 
 
3. Bronchoalveolar lavage fluid studies (Study I)  
 
Each patient underwent HRCT, bronchoscopy, BAL, spirometry and diffusion capacity 
measurements. Healthy control subjects were evaluated with BAL and spirometry. All 
symptomatic subjects were examined in Helsinki University Central Hospital (Helsinki, 
Finland) and Jyväskylä Central Hospital (Jyväskylä, Finland). IPF, NSIP and related interstitial 
disorders and pulmonary sarcoidosis were diagnosed according to the diagnostic criteria set by 
the American Thoracic Society and the European Respiratory Society (ATS/ERS 2000). 
Sarcoidosis patients were further grouped to patients with clear parenchymal changes 
(parenchymal sarcoidosis) and patients with only lymph node enlargement and slight 
nodularity in HRCT (non-parenchymal sarcoidosis).  
 
Lung function parameter tests included flow volume spirometry and single breath diffusion 
capacity. Thoracoscopic lung biopsy was available from two patients with IPF, three with 
NSIP and related interstitial disorders and three with sarcoidosis. If no lung biopsy was 
performed, diagnosis was based on typical clinical findings and characteristic findings at 
HRCT evaluated by an expert pulmonary radiologist as suggested by the guidelines of the 
American Thoracic Society and the European Respiratory Society (ATS/ERS 2000, 2002). 
Patients with NSIP and related interstitial disorders who had not undergone lung biopsy had 
typical HRCT findings and an objective response to steroid treatment. Subjects with prolonged 
cough (at least two months) without any interstitial or alveolar abnormalities in HRCT and 
with a normal cell profile in the BAL fluid were added to the study as a disease control group. 
They underwent basic laboratory and allergic tests, spirometry, HRCT, bronchofiberscopy and 
BAL to exclude any other diseases (Table 7).  
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Table 7. Patient characteristics for the BAL fluid studies. 
BAL fluid samples
Control 7
IPF/UIP 7
NSIP 5
Sarcoidosis
  Parenchymal sarcoidosis
  Non-parenchymal sarcoidosis
7
9
Cough 6
Bronchoalveolar lavage was performed under local anaesthesia in a representative lung seg-
ment with 200 ml of sterile 0.9% saline according to the standard procedure. Recovered fluid 
was stored on ice at all times and processed within one hour of collection. The fluid was then 
centrifuged at 400xg for 10 min at +4ºC to separate the cells from the supernatant. Total cell 
numbers were determined using a haemocytometer and the cells were used for differential cell 
counts and fluorescence-activated cell sorter analyses. Excess cells were regained by centrifug-
ing the remaining cell suspension at 400xg for 10 min at +4ºC and cytocentrifuged on glass 
slides at 450 rpm for 6 min at room temperature for immunocytochemical analyses. The total 
MMP-7 concentration from noncellular supernatants of BAL fluid was analysed with the 
Quantikine Human MMP-7 (total) enzyme-linked immunosorbent assay (ELISA) (R&D Sys-
tems) according to the manufacturer’s instructions.
4. Cell culture (Studies II, V)
4.1. Cell lines
Normal human pulmonary fibroblasts (CCL-190, American Type Culture Collection, Manas-
sas, VA, USA) and IPF fibroblasts (CCL-134 and CCL-191, American Type Culture Collec-
tion) were used in the in vitro studies. In addition, primary human IPF fibroblasts (IPF-U.N., 
IPF-III, IPF-IV, IPF-V) were propagated from explanted lung transplants of patients with IPF 
and biopsy-proven UIP (Table 8). Lung tissue was dispersed mechanically and suspended in 
Dulbecco’s Modified Eagle’s Medium (DMEM) (Biomedicum Helsinki, Helsinki, Finland) 
supplemented with 15% fetal calf serum (FCS) (PromoCell GmbH, Heidelberg, Germany). 
Cells were allowed to attach overnight, washed and grown to confluence. All further cell cul-
turing was performed in DMEM supplemented with either 1% or 10% FCS, 2 mmol/ml glu-
tamine (Biomedicum Helsinki, Helsinki, Finland), 10,000 IU/ml penicillin/streptomycin (Pro-
moCell) and 1.4 μg/ml amphotericin B (Gibco BRL, Invitrogen Ltd, Paisley, UK). Cells were 
used at passage numbers two to nine. 
Normal human dermal fibroblasts and dermal fibroblasts from a patient with localized 
scleroderma (provided by Dr. Olli Saksela, Helsinki University Hospital, Helsinki, Finland) 
and human dermal fibroblasts from a patient with systemic sclerosis (CRL-1108, American 
Type Culture Collection) were cultured in culture medium supplemented with 10% FCS (Study 
II).
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Table 8. Cell lines used in the cell culture studies. 
Study II Study V
Normal human pulmonary fibroblasts
  CCL-190 + +
IPF fibroblasts
  CCL-134
  CCL-191
+
+
+
-
Primary IPF/UIP fibroblasts
  IPF-U.N.
  IPF-III
  IPF-IV
  IPF-V
+
-
-
-
+
+
+
+
Dermal fibroblasts
  Normal human dermal fibroblasts
  Systemic sclerosis
+
+
-
-
4.2. Migration assay
Human pulmonary fibroblast migration was quantified using Transwell two-chamber culture 
plates (Corning Inc., Corning, NY, USA) with polycarbonate membranes and a pore size of 8 
μm. The membranes were coated with 1μg/ml fibronectin (Sigma-Aldrich, Steinheim, Ger-
many) in PBS. 
The primary human IPF fibroblasts migrated poorly in response to stimulation with 10% se-
rum. The effects of growth-stimulatory growth factors were tested in order to mimic the in vivo
situation and to be able to achieve a strong migratory effect for the following imatinib mesylate 
inhibition studies. 1% FCS-DMEM was inserted to the lower chambers, while 100 μl of cell 
suspension containing 1 million cells/ml normal human pulmonary fibroblasts (CCL-190), IPF 
fibroblasts (CCL-134) or primary human IPF fibroblasts (IPF-U.N., IPF-III, IPF-IV) were 
placed in the upper chambers. Cells were allowed to attach at 37˚C for an hour after which the 
medium in the lower chamber was replaced with 50 ng/ml of EGF, 50 ng/ml of PDGF-AB or 
50 ng/ml of PDGF-BB (all growth factors from Neo Markers) in 1% FCS-DMEM. Control 
wells were treated with 1% or 10% FCS-DMEM. 
4.3. Imatinib mesylate inhibition
Inhibition of cell migration was assessed with normal human pulmonary fibroblasts (CCL-
190), IPF fibroblasts (CCL-134) and primary human IPF fibroblasts (IPF-U.N.). Based on the 
previous stimulation experiments, fibroblast migration was enhanced with 1% FCS-DMEM 
supplemented with 50 ng/ml EGF and 50 ng/ml PDGF-AB in the lower chamber. The protein 
tyrosine kinase inhibitor imatinib mesylate was kindly provided by Dr. Elisabeth Buchdunger 
(Novartis Pharma AG, Basel, Switzerland) and solubilized in distilled water to yield a stock 
concentration of 10mM.  For the inhibition experiments, imatinib mesylate was further diluted 
with 1% FCS-DMEM and 0.1 μM, 1 μM or 10 μM imatinib mesylate was added to the upper 
cell culture chambers. Negative control cells were treated with 1% FCS-DMEM and positive 
controls with 1% FCS-DMEM supplemented with 50 ng/ml of EGF and 50 ng/ml of PDGF-
AB. The cells were allowed to migrate for 24 h and the membranes were detached, the cells 
fixed with ice-cold methanol and stained with Mayer’s haematoxylin (Reagena Ltd, Toivala, 
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Finland). Cells on the upper surface of the membrane were wiped off. The cells that had mi-
grated through the pores to the lower surface were quantified by counting specified cross-
sectional fields on a light microscope using 40x magnification. 
4.4. Apoptosis assay
Apoptosis assay (NucView™ 488 Caspase-3 Assay Kit for Live Cells, Biotium, Inc., Hayward, 
CA, USA) was performed in order to assess whether imatinib mesylate could induce apoptosis 
in human pulmonary fibroblasts. Normal human pulmonary fibroblasts (CCL-190) and primary 
human IPF fibroblasts (IPF-U.N., IPF-III, IPF-IV, IPF-IV) were grown on glass coverslips and 
treated with 0.1 μM, 1 μM or 10 μM imatinib mesylate. Control cells were incubated with se-
rum free DMEM to achieve the induction of apoptosis. After 24 hours the growth medium was 
removed and the cells were incubated with 1 μM NucView™ 488 Caspase-3 substrate solution 
for 15 minutes. The slides were then examined under a fluorescence microscope and represen-
tative images were taken for the analyses of the degree of apoptosis.
4.5. Immunofluorescence
In order to assess the expression and localization of the imatinib mesylate target proteins, nor-
mal and primary human IPF/UIP fibroblasts were grown to confluence on glass coverslips 
(Nunc, Roskilde, Denmark). Coverslips were then washed with PBS and the cells were fixed 
with methanol at –20˚C. To prevent non-specific antibody binding, the cells were incubated in 
PBS containing 1% bovine serum albumin for 30 minutes. The cells were then incubated for 
one hour with the primary antibodies (PDGFR, PDGFR, c-Abl or c-Kit) diluted in PBS con-
taining 0.5% bovine serum albumin. Primary antibody binding was detected using fluorescein 
conjugated secondary antibodies. Cell nuclei were counterstained with 4’,6-diamino-2-
phenylindole (Invitrogen) and the coverslips were mounted with Vectashield HardSet mount-
ing medium (Vector Laboratories). Images were taken with an Olympus U-CMAD3 camera 
(Olympus Corporation, Japan) and analyzed with QuickPHOTO CAMERA 2.1 software (Pro-
micra, Czech Republic).
4.6. TGF- activity assay
TGF- activity was analyzed from the culture medium of normal human pulmonary fibroblasts 
(CCL-190) and IPF fibroblasts (CCL-134, CCL-191). Serum-free medium was harvested from 
fibroblasts and aliquots of the media from the same number of cells were used directly to assay 
TGF- activity. Total TGF- was analyzed after heat treatment that activated the latent forms 
of TGF- (Abe et al. 1994). The results are presented as relative values of TGF- activity when 
the activity in control medium is set to 1. 
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4.7. BMP-4 signalling assay
To assess endogenous BMP signalling, normal human pulmonary fibroblasts (CCL-190) and 
IPF fibroblasts (CCL-134, CCL-191) were transfected with 2 μg of BMP-responsive element 
(BRE)2-luciferase promoter construct together with a pRL-TK vector (Promega, Madison, WI, 
USA) containing Renilla luciferase cDNA. Transfections were performed with FuGENE 6 
transfection reagent (Roche, Basel, Switzerland). The cells were lysed 48 hours after transfec-
tion and the luciferase indicator gene activities were measured according to the manufacturer’s 
instructions with the dual luciferase kit (Promega). To assess responsiveness to exogenous 
BMP-4, normal and IPF/UIP fibroblasts were treated with 5, 15 or 25 ng/ml of BMP-4 (R&D 
Systems) for 16 hours followed by luciferase indicator gene activity analyses.
The levels of total (Smad1, Santa Cruz) and phosphorylated Smad1 (P-Smad1, Dr. Peter ten 
Dijke), a BMP downstream signalling molecule, were analyzed from normal human pulmonary 
fibroblasts and IPF/UIP fibroblast (CCL-134, CCL-190) lysates by immunoblotting.
4.8. Northern blot
Northern hybridization was performed to analyze TGF-, gremlin and BMP-4 mRNA expres-
sion levels in normal pulmonary fibroblasts, IPF/UIP fibroblasts and dermal scleroderma fi-
broblasts. Total cellular RNA was isolated with the RNeasy mini kit (Qiagen, Hilden, Ger-
many). Ten micrograms of total RNA were fractioned on 1.2% agarose gels and transferred to 
Hybond-N nylon membranes (Amersham, Uppsala, Sweden). The hydridizations were per-
formed at 68°C. cDNA probes for the genes of interest were labelled using Ready-To-Go DNA 
labelling kit (Amersham) and detection perfomed by fluorography.
5. Animal experiments (Study V)
Animal experiments were reviewed and approved by the University of Pittsburgh Institutional 
Animal Care and Use Committee (Pittsburgh, Pennsylvania, USA). Laboratory animals re-
ceived humane care and all experiments were performed according to the Helsinki convention 
guidelines. All animal experiments were performed by Tim D. Oury´s research group in the
University of Pittsburgh, Pennsylvania, USA. 
Six to eight week old male C57BL6 mice were divided into three groups (5–8 mice per group). 
Mice were injected intraperitoneally daily with either vehicle only, 10 mg/kg (Krebs et al. 
2005, Tikkanen et al. 2006) or 50 mg/kg (Daniels et al. 2004, Aono et al. 2005, Chaudhary et 
al. 2006) imatinib mesylate in distilled water, starting one day before intratracheal instillation 
of titanium dioxide (TiO2, from Sigma, St. Louis, MO, USA) or 0.1 mg crocidolite asbestos 
(National Institutes of Environmental Health Sciences, Research Triangle Park, NC, USA). 
TiO2 was used as an inert particulate control in order to ensure that the changes observed in the 
lungs of the asbestos-treated mice were not caused by a non-specific response to particles in 
the lung (Kamp et al. 2002). Treatment with 10 mg/kg/day imatinib mesylate has been shown 
to lead to a plasma level of approximately 2 μM and to maintain the plasma concentration of 
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imatinib mesylate above the level required for inhibition of the PDGFRs (Krebs et al. 2005, 
Buchdunger et al. 2000). This mimics the human dosage of 400 mg/day, although 50 
mg/kg/day is more commonly used in experimental animal studies. A concentration as low as
0.1 μM imatinib mesylate is sufficient to cause a 50% reduction in cellular PDGFR-, PDGFR-
 and c-Kit tyrosine kinase activity. 
Mice were sacrificed 14 days post-treatment and BAL fluid was obtained by intratracheal in-
stallation and recovery of 0.8 ml 0.9% saline. Total protein content in BAL fluid was deter-
mined using Coomassie Plus Protein Assay Reagent (Pierce, Rockford, IL, USA).  Total white 
blood cell counts were obtained with Beckman Z1 Coulter particle counter (Beckman Coulter, 
Fullerton, CA, USA).  To obtain a differential cell count, BAL fluid samples were cytospun to 
glass slides and the number of macrophages, neutrophils and lymphocytes were counted under 
a microscope.
The hydroxyproline assay was performed in order to assess the collagen content in the lungs of 
asbestos-exposed mice.  Whole lungs were removed, dried and acid hydrolyzed at 110°C for 
24 h in sealed, oxygen-purged glass ampoules containing 2 ml of 6 N HCl. Samples were dried 
again, resuspended in 1.5 ml PBS and incubated at 60°C for one hour. Samples were then cen-
trifuged at 13,000 rpm and the supernatant was collected for hydroxyproline analysis with the
chloramine-T (Tan et al. 2004).
Lungs from some mice were inflation fixed with 10% buffered formalin and paraffin embedded 
for histological analysis. Haematoxylin and eosin stained lung sections were scored by a pa-
thologist blinded to the sample groups. Individual fields were scored in the entire lung, begin-
ning peripherally.  To be counted, each field had to contain terminal bronchioles/ alveolar tis-
sue in > 50% of the field. Scoring in each field was based on the percentage of terminal bron-
chioles/alveolar tissue with interstitial fibrosis according to the following scale: 0 = no fibrosis, 
1 = up to 25%, 2 = 25–50%, 3 = 50–75%, 4 = 75–100% fibrosis.
6. Statistical analyses
Data are expressed as mean ± the standard error of the mean (SEM). Data were analysed using 
SPSS for Windows (SPSS Inc. Chicago, IL, USA). Significances of inter-group differences be-
tween two groups were analyzed with the Mann-Whitney U-test or Student’s t-test, as appro-
priate. Significances of differences between several groups were assessed using the non-
parametric Kruskall-Wallis analysis of variance. Data from the animal experiments were ana-
lyzed using one-way ANOVA, followed by group comparisons using Newman-Keuls multiple 
comparison tests. Spearmann’s rank correlation analysis for nonparametric data was used to 
correlate data with clinical parameters and cellular profiles. A p value of < 0.05 was considered 
to be statistically significant. 
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RESULTS
1. Specific markers of idiopathic pulmonary fibrosis 
1.1. Matrix metalloproteinase-7 (Study I)
MMP-7 protein levels in the BAL fluid of patients with idiopathic interstitial pneumonias were 
measured and compared in order to assess whether they could be used in the differential diag-
nostics of these diseases. The mean concentration of total MMP-7 was significantly increased 
in IPF/UIP, NSIP and related interstitial disorders and sarcoidosis when compared to healthy 
controls (p = 0.007). A three-fold elevation was detected even in the BAL fluid of patients with 
prolonged idiopathic cough when compared to healthy controls although it was not statistically 
significant. The MMP-7 concentration did not differ between parenchymal and nonparenchy-
mal sarcoidosis and no statistically significant differences were observed between the different 
interstitial lung diseases (Figure 3).
BAL fluid MMP-7 levels were correlated with pulmonary function tests to evaluate their value 
in the assessment of disease severity. A weak negative correlation was found between BAL 
fluid MMP-7 levels and FVC (r = -0.348, p = 0.02, n = 42) and between MMP-7 and the per-
centage of BAL fluid macrophages (r = -0.395, p = 0.008, n = 42). No statistically significant 
correlation was found between MMP-7 and the absolute numbers of macrophages or with the 
lymphocyte counts. 
Figure 3. MMP-7 protein levels (ng/ml) in the BAL fluid of healthy control subjects and patients with IPF/UIP, 
NSIP, parenchymal sarcoidosis, non-parenchymal sarcoidosis and idiopathic cough.
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MMP-7 protein was localized predominantly in the IPF/UIP (n = 7) parenchyma (fibroblastic 
foci) and vascular smooth muscle cells of the arterial wall. MMP-7 positive cells were also 
found in hyperplastic epithelium. In NSIP (n = 6), MMP-7 was localized in proximity to the in-
flammatory cells situated beneath the alveolar epithelium. In pulmonary sarcoidosis (n = 3), the 
granulomatous lesions displayed positive immunoreactivity for MMP-7. No marked MMP-7 
immunoreactivity was detected in the healthy control lung specimens (n = 3).
1.2. Gremlin overexpression in IPF/UIP (Study II)
The amount of active and latent TGF- secreted by IPF/UIP (CCL-134, CCL191) and normal 
human fibroblasts (CCL-190) was analyzed from the cell culture medium. IPF/UIP fibroblasts 
secreted approximately threefold higher levels of active TGF- and a 1.5-fold higher amount of 
total TGF- when compared to normal fibroblasts. This indicates that IPF/UIP fibroblasts are 
able to activate more latent TGF-, most of which was identified by Northern hybridization as 
the TGF-1 form. 
The expressions of gremlin and BMP-4 mRNA in cultured normal human pulmonary fibro-
blasts (CCL-190) and IPF/UIP fibroblasts (CCL-134, CCL191) were analyzed in order to as-
sess the effects of increased TGF- secretion. mRNA expression levels of the BMP inhibitor 
gremlin were increased up to fivefold in IPF/UIP fibroblasts, but BMP-4 mRNA levels were 
not altered. Gremlin mRNA expression was analyzed also in dermal scleroderma fibroblasts in 
order to assess whether its overexpression is a general feature of fibrotic diseases. Although 
gremlin mRNA was highly expressed in primary human pulmonary fibroblasts from IPF/UIP 
patients (IPF-U.N.), no corresponding overexpression was found in the skin fibroblasts of 
scleroderma patients, suggesting that the overexpression might be a useful indicator of IPF/UIP 
and lung fibrosis rather than fibrosis in general. 
Since gremlin functions as a BMP-4 inhibitor, the effects of increased gremlin expression on 
BMP signalling in cultured normal (CCL-190) and IPF/UIP fibroblasts (CCL-134, CCL191)
were evaluated. Analyses of BMP signalling activity were performed with a BMP-responsive 
promoter construct and the results showed decreased levels of endogenous BMP signalling in 
IPF/UIP fibroblasts. The responsiveness to exogenous BMP-4 (5, 15 or 25 ng/ml) was also de-
creased in IPF/UIP fibroblasts when compared to normal human pulmonary fibroblasts. Im-
munoblotting revealed that the total protein levels of Smad1, an intracellular downstream sig-
nalling molecule of BMPs, remained unaltered in normal human pulmonary fibroblasts and 
IPF/UIP fibroblasts that were treated with BMP-4 (5, 15 or 25 ng/ml). Phosphorylation of 
Smad1, indicative of its activation and transfer to the nucleus, was however decreased in 
IPF/UIP fibroblasts, evidence of an impairment in BMP-4 signalling.
Immunohistochemistry was performed to visualize localization of gremlin and BMP-4 in 
IPF/UIP and normal lung tissue. Intense gremlin immunoreactivity was detected in IPF/UIP 
lung biopsies both in the fibrotic lung parenchyma and in the fibroblastic foci.  Normal lung 
tissue showed gremlin localization in alveolar epithelium and alveolar macrophages. 
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To verify the overexpression already detected in cultured IPF/UIP fibroblasts, lung tissue sam-
ples of IPF/UIP patients were used to analyze gremlin mRNA expression levels. The gremlin 
mRNA levels were upregulated by up to 35-fold (p < 0.05) in the lungs of patients with 
IPF/UIP (n = 6) when compared to normal control samples (n =6) (Figure 4). BMP-4 and -7 
mRNA expression levels did not differ between IPF/UIP and normal control samples, but 
BMP-2 levels were reduced by approximately 60% in IPF/UIP when compared to normal con-
trol samples. 
Figure 4. Relative expression of gremlin mRNA in normal control and IPF/UIP lungs.
0
5
10
15
20
25
30
35
40
R
e
la
ti
v
e
e
x
p
re
s
s
io
n
o
f
g
re
m
li
n
m
R
N
A
C
trl
C
trl
C
trl
C
trl
C
trl
C
trl
IP
F/
U
IP
IP
F/
U
IP
IP
F/
U
IP
IP
F/
U
IP
IP
F/
U
IP
IP
F/
U
IP
1.3. Gremlin expression and localization in IPF/UIP vs. NSIP (Study III)
Gremlin protein expression and localization in IPF/UIP and NSIP lung tissue was visualized by 
immunohistochemistry in order to determine if there were differences between these disorders. 
When the areas of positive staining were compared using morphometry, a distinct difference in 
the localization of gremlin between the IPF/UIP and NSIP tissue samples was found. In 
IPF/UIP (n = 24), gremlin was detected mainly in the thickened lung parenchyma and in the 
endothelium of small capillaries, whereas in NSIP (n = 12) it was observed predominantly in 
the alveolar epithelium. The percentage of gremlin positive area was higher in IPF/UIP (5.1 ± 
0.6) than in NSIP (1.8 ± 0.7) (n = 36, p < 0.0001).
-SMA and gremlin double staining was also performed to demonstrate the difference in grem-
lin localization between IPF/UIP and NSIP. There was more -SMA positive staining in 
IPF/UIP biopsies than in NSIP biopsies (p < 0.0001), and the amount of gremlin immunoreac-
tivity correlated weakly with -SMA immunoreactivity (r = 0.37, p = 0.03, n = 33). Some 
overlapping in the immunostaining patterns was however detected and a few NSIP biopsies 
also revealed intense parenchymal immunoreactivity.  
BMP-4 positive cells were localized to the alveolar walls of IPF/UIP and NSIP, with the high-
est numbers being found in NSIP (Figure 5).
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Figure 5. The percentage of BMP-4 positive cells in IPF/UIP and NSIP lung.
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The IPF/UIP group was divided further into early (patients that underwent a diagnostic biopsy, 
n = 19) and advanced (patients that had undergone transplantation, n = 5) stages of the disease 
in order to determine whether gremlin expression changes during disease progression. The 
proportion of gremlin positive area was highest in advanced IPF/UIP (6.065 ± 0.619, p = 0.001 
for IPF/UIP advanced vs. NSIP and lowest in NSIP (1.775 ± 0.657) (Figure 6). The area of 
gremlin positive staining in the lung tissue samples correlated negatively with IPF/UIP and 
NSIP patients’ FVC (r = - 0.403, p = 0.02, n = 34).
Figure 6. Morphometric analysis of gremlin protein expression in IPF/UIP and NSIP lung. Diagnostic IPF/UIP 
biopsies are named IPF/UIP early and samples obtained from lung transplantation IPF/UIP advanced.
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Both advanced IPF/UIP (n = 4) and NSIP (n = 6) biopsies exhibited higher levels of gremlin 
mRNA (p = 0.008 and p = 0.007, respectively) than the control lung (n = 7). Gremlin mRNA 
levels were also higher in patients with end-stage fibrosis than in patients with early disease (p 
= 0.01), but there was no difference between the early IPF/UIP and NSIP. The mRNA expres-
sion levels of BMP-4 were elevated in NSIP and lowest in the advanced IPF/UIP (p = 0.006) 
when compared to normal/healthy controls (Figure 7).
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Figure 7. Gremlin and BMP-4 mRNA expression in control lung tissue and biopsies from patients with IPF/UIP 
and NSIP. 
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Gremlin and BMP-4 mRNA levels of IPF/UIP early (n = 6), IPF/UIP advanced (n = 4) and 
NSIP (n = 6) patients were correlated with pulmonary functions in order to see whether they 
would reflect disease severity. There was a negative correlation between the specific diffusion 
capacity corrected for alveolar volume (DLCO/VA) and gremlin mRNA levels (r = -0.69, p = 
0.007). BMP-4 mRNA levels correlated positively with FVC (r = 0.801, p < 0.0001), diffusion 
capacity (r = 0.601, p = 0.01) and DLCO/VA (r = 0.594, p = 0.02).
2. Profibrotic growth factor receptors and signalling 
2.1. Peroxiredoxin II and PDGF receptors in the IPF/UIP lung (Study IV)
Prx expression in the human lung tissue, especially in the fibroblastic foci, was visualized by 
immunohistochemistry. Prx I-Prx VI was localized in the IPF/UIP epithelium and alveolar 
macrophages.  The percentage of Prx II positive area in the fibroblastic foci was smaller than in 
the other parenchymal areas in IPF/UIP (p = 0.03) and also smaller than in the hyperplastic epi-
thelium of IPF/UIP (p = 0.01) (Figure 8). There were no differences in the Prx II positive area 
in the epithelium between normal and diseased lung. 
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Figure 8. The percentage of Prx II positive area in the IPF/UIP lung.
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The oxidation state of Prx II was analyzed by non-reducing (detecting oxidated, monomeric 
Prx II) and standard (detecting reduced Prx II) western blotting. The sum intensities of the di-
meric and monomeric Prx II forms in the non-reducing western blot were significantly lower in 
IPF/UIP than in the control lungs (p = 0.02). Furthermore, the intensities of both bands were 
lower in the IPF/UIP when measured separately (p = 0.02).  Since the hyperoxidized forms are 
not necessarily monomers, possible Prx II hyperoxidation was further investigated by a stan-
dard western blot technigue with sulfinic-acid-specific antibody. This revealed a decrease in 
the level of the hyperoxidized Prx II in the IPF/UIP lungs.  This result is in concordance with 
the overall decrease of Prx II levels in the IPF/UIP lungs. 
Since cysteine oxidation of Prxs causes a change in the protein charge reflected by a spot shift 
within the two-dimensional gel electrophoresis (2-DE), the oxidation stage of Prx II in vivo
was further evaluated by 2-DE of control (n=4) and IPF/UIP (n=4) lung tissue samples. In 
agreement with the western blots, a slight decrease in the Prx II level was observed in IPF/UIP 
lungs. However, the Prx II spot showed no shift in 2-DE gels of control or IPF/UIP indicating 
no difference in the oxidation status of the Prx II catalytic cysteines. These data indicate that 
the majority of Prx II in the control as well as IPF/UIP lungs is not irreversibly oxidized.
The immunoreactivity to PDGFR- and PDGFR- was elevated in IPF/UIP parenchyma, but 
again the fibroblastic foci showed only minor immunoreactivity to the PDGFRs (Figure 9).
Similarly, Ki67 positive proliferating cells were observed predominantly outside the fibroblas-
tic foci. Nitrotyrosine was used as a marker for oxidative/nitrosative stress in the IPF/UIP lungs 
since it reflects both superoxide- and nitric oxide-mediated reactions in the cells. Nitrotyrosine 
positive cells localized to the epithelium and inflammatory cells but again the fibroblastic foci
showed only weak positivity or remained negative (Figure 10).
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Figure 9. The percentages of PDGFR- and PDGFR- positive area in the IPF/UIP lung. 
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Figure 10. The percentages of Ki67 and nitrotyrosine positive area in the IPF/UIP lung.
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2.2. Inhibition of profibrotic signalling (Study V)
10 mg/kg/day of imatinib mesylate prevented crocidolite asbestos-induced fibrosis in mice and 
decreased lung collagen deposition significantly (p < 0.001). Total protein levels and inflam-
matory cell accumulation in the BAL fluid were determined in order to assess the effects of 
imatinib mesylate on the asbestos-induced lung inflammatory response. When compared to 
TiO2-treated controls, asbestos-treated mice had greater total BAL fluid protein and cell num-
bers. However, neither 10 mg/kg/day nor 50 mg/kg/day imatinib mesylate could prevent asbes-
tos-induced inflammatory cell (mainly neutrophilic) infiltration, suggesting that imatinib mesy-
late may be a specific inhibitor of profibrotic signalling. 
Immunofluorescence stainings were performed to determine whether cultured human pulmo-
nary fibroblasts expressed the protein kinases inhibited by imatinib mesylate. In vitro, primary 
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human IPF fibroblasts expressed Abl (nuclei), PDGFR- (cell membrane), PDGFR- (cell 
membrane), but not c-kit. Normal human pulmonary fibroblasts displayed only weak positive 
c-kit staining in the cytoplasm. 
Growth factors such as EGF, IGF and PDGF have been shown to stimulate pulmonary fibro-
blast proliferation (Sasaki et al. 2000, Hetzel et al. 2005). Here their stimulatory effects were 
tested on human pulmonary fibroblast migration as well as on the inhibition of this migration 
by imatinib mesylate. The effects of 50 ng/ml of EGF, PDGF-AB or PDGF-BB stimulation 
were stronger on normal human pulmonary fibroblast migration than on IPF fibroblasts (Figure 
11). Treatment with 1 μM imatinib mesylate reduced EGF-and PDGF-AB-stimulated migra-
tion of normal human pulmonary fibroblasts by 24% (p = 0.002), in IPF fibroblasts 20% and in 
primary human IPF fibroblasts by 40% (p < 0.0001) when compared to the respective control 
cells (Figure 12).
Figure 11. The effect of growth factor stimulation of human pulmonary fibroblast migration. Normal (CCL-190) 
and IPF (CCL-134) fibroblasts as well as four primary fibroblast cell lines propagated from tissue biopsies of pa-
tients with IPF which were stimulated with 10% FCS, 50 ng/ml EGF, 50 ng/ml PDGF-AB or 50 ng/ml PDGF-BB. 
Control cells were treated with 1% serum. The results of the primary IPF fibroblasts are presented as the mean of 
the four cell lines.
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Figure 12 The inhibitory effect of 1 μM imatinib mesylate on human pulmonary fibroblast migration. Normal 
(CCL-190), IPF (CCL-134) fibroblasts and primary IPF fibroblast (IPF-U.N.) were stimulated with 50 ng/ml EGF 
and 50 ng/ml PDGF-AB and treated simultaneously with 1 μM imatinib mesylate. Data are presented as the per-
centage of inhibited cells when compared to control cells stimulated with 50 ng/ml EGF and 50 ng/ml PDGF-AB.
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Normal human pulmonary fibroblasts and primary human IPF fibroblasts were treated with in-
creasing concentrations of imatinib mesylate in order to assess whether imatinib mesylate 
could induce apoptosis in human pulmonary fibroblasts in vitro. Control cells were incubated 
with serum free DMEM for the induction of apoptosis. The amount of apoptotic cells seemed 
to the higher in the serum-starved control cells than in any of the cell lines treated with 0.1 μM, 
1.0 μM or 10 μM of imatinib mesylate.
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DISCUSSION
Idiopathic interstitial pneumonias represent pulmonary diseases with unknown aetiologies. The 
variability seen in the disease course of IPF/UIP and in the prognosis of different idiopathic in-
terstitial pneumonias emphasizes the need for an early and accurate differential diagnosis 
(Dempsey et al. 2006, Kim DS et al. 2006).
IPF patients are treated with corticosteroids and immunosuppressive agents, but due to the poor 
efficacy of these drugs, novel treatment strategies are needed. Since IPF represents a syndrome 
involving numerous growth factors, cytokines and other mediators, it is unlikely that targeting 
any single pathway will be efficient and multiple approaches may need to be utilized (Maher et 
al. 2007). There are many possible treatment strategies for IPF are numerous including agents 
that prevent epithelial cell damage, fibroblast proliferation and collagen synthesis, agents that 
inhibit myofibroblast differentiation, oxidative stress and angiogenesis and agents that interfere 
with signal transduction pathways (Gharaee-Kermani et al. 2007). Novel approaches such as 
laser capture microdissection, genomics and proteomics can be utilized to identify critical 
genes and signalling molecules that are involved in fibrosis. Inhibitors of these signalling cas-
cades can be used in animal models to determine the functional and phenotypic outcome of the 
modified fibrotic responses. Knock-out animal models can help in elucidating the role of speci-
fied genes in the pathogenesis of pulmonary fibrosis. Nonetheless, a better understanding of the 
molecular mechanisms underlying fibrogenesis is crucial before one can embark on the rational
development of new therapeutic strategies. 
1. Matrix metalloproteinase-7 as a specific marker of idiopathic pulmonary fibrosis 
Microarray studies have revealed a number of potential genes whose expression profiles are al-
tered in IPF, and MMP-7 has been considered a promising marker for IPF diagnostics (Cos-
grove et al. 2002, Zuo et al. 2002, Kelly et al. 2006, Selman et al. 2006). MMP-7 gene expres-
sion has been investigated by comparing healthy lung and IPF lung tissue homogenates (Cos-
grove et al. 2002, Zuo et al. 2002, Selman et al. 2006) or defined in areas of the lung by laser 
capture microdissection (Kelly et al. 2006). However, little attention has been paid to its levels 
in other interstitial lung diseases. 
The MMP-7 protein levels were analyzed in the BAL fluid of patients with IPF and compared 
with other interstitial lung diseases (NSIP, sarcoidosis). MMP-7 determinations were made 
from BAL fluid samples split off from routine diagnostic samples in order to assess the true 
differential diagnostic value of MMP-7. The results were in line with previous studies showing 
elevated MMP-7 expression in IPF (Cosgrove et al. 2002, Zuo et al. 2002, Selman et al. 2006). 
However, our study revealed that even though the localization of MMP-7 in the lung biopsies 
varied between the different interstitial disorders, elevated BAL fluid MMP-7 levels were not 
specific for IPF/UIP. This indicates that BAL fluid MMP-7 levels cannot be used as a specific 
differential diagnostic marker for IPF/UIP. Similar results were reported when MMP-7 levels 
in the BAL fluid of patients with UIP or cryptogenic organizing pneumonia were compared 
(Huh et al. 2008). Although MMP-7 levels were elevated in both disease groups when com-
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pared to normal control subjects, no significant difference was found between UIP and crypto-
genic organizing pneumonia (Huh et al. 2008). The contradictory results provided by previous 
evaluation of the diagnostic value of BAL in the differential diagnosis of NSIP and IPF (Veera-
raghavan et al. 2003, Ryu et al. 2007) further emphasize that evaluation of MMP-7 levels 
seems mostly effective in excluding other causes of pulmonary impairment.
Upregulated MMP-7 immunoreactivity has been previously detected in the epithelium adjacent 
to fibroblastic foci, in hyperplastic type 2 pneumocytes and in areas of wound repair (Cosgrove 
et al. 2002, Zuo et al. 2002, Kelly et al. 2006, Selman et al. 2006). In agreement, our results 
demonstrated MMP-7 immunoreactivity at the sites of parenchymal fibrosis or inflammation. 
Our results also emphasize the value of inclusion of disease control subjects in the studies 
scanning for disease-specific diagnostic markers. Many studies are designed to compare sam-
ples from healthy and diseased lung, but this may lead to erroneous misinterpretations of the 
specificity of the diagnostic molecules and their alterations. As these results demonstrate, diag-
nostic markers may be similarly elevated e.g. in patients with prolonged cough. The weak 
negative correlation between BAL fluid MMP-7 levels and FVC suggests that although MMP-
7 cannot be used to differentiate between parenchymal disorders, it could be considered as a 
marker of pulmonary tissue disturbances. MMP-7 degrades the TGF--binding protein,
decorin, releasing TGF- from the extracellular matrix (Imai et al. 1997) and thus elevated 
MMP-7 levels might contribute to pulmonary fibrosis by enhancing TGF-  activation.
2. Gremlin expression and localization in IPF/UIP and NSIP  
Gremlin plays an important role during lung and kidney development (Lu et al. 2001, Michos 
et al. 2004). In the present study, gremlin mRNA was found to be overexpressed in cultured fi-
broblasts isolated from IPF/UIP patients and in the lungs of patients with IPF/UIP, whereas no 
overexpression was found in the skin fibroblasts of scleroderma patients. The differential diag-
nosis of IPF and NSIP can be difficult and additional diagnostic tools such as microarray 
analyses (Selman et al. 2006) could provide much needed support. However, no differences in 
the gremlin mRNA levels of early IPF/UIP and NSIP biopsies were found, indicating that 
gremlin is not useful in the differential diagnostics of the early stages of IPF/UIP and NSIP. In-
stead, these findings suggest that elevated gremlin mRNA expression might be a beneficial in-
dicator of a more advanced disease stage, independent of the diagnosis, and lung fibrosis rather 
than fibrosis in general. Increased gremlin expression in the IPF/UIP lungs may contribute to 
inadequate BMP-4-signalling and impaired epithelial repair as well as sustained TGF- activa-
tion, although it remains unclear how the TGF--binding proteins and latent TGF- are regu-
lated in the IPF fibroblasts. 
In IPF/UIP biopsies, gremlin was localized mainly to the thickened lung parenchyma where it 
may promote the persistence of myofibroblasts. In normal lung tissue and NSIP, gremlin was 
observed in the alveolar epithelium where it may help to maintain epithelial integrity. This dif-
ference in the localization pattern of gremlin between IPF/UIP and NSIP suggests that paren-
chymal gremlin immunoreactivity is related to a UIP-type interstitial pneumonia. However, 
significant overlapping was observed, because some of the NSIP samples did show similar 
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parenchymal gremlin immunoreactivity as the IPF/UIP samples. This finding confirms the dif-
ficulties in the histopathological differential diagnosis of IPF/UIP and NSIP and emphasizes 
the need for more sophisticated methods in order to confirm whether gremlin may be useful as 
a differential diagnostic marker. Future studies will determine whether this finding can evolve 
into real diagnostic or therapeutic applications. 
Studies with experimental animal models have suggested that inhibition of gremlin with BMPs 
may have a protective and therapeutic role in fibrosis (Zeisberg et al. 2003, 2005, Sugimoto et 
al. 2007, Myllärniemi et al. 2008). In the present study, BMP-4 mRNA expression levels were 
downregulated in the most advanced stages of IPF/UIP and correlated positively with lung 
function parameters, suggesting that increased gremlin expression may affect BMP-4 levels.  
BMP-4 is also a negative regulator of intracellular TGF- signalling (Chen D et al. 2004).
However, the finding that TGF-1 knock-out mice die due to inflammation (Letterio and Rob-
erts 1996) has raised some concerns about the use of TGF- inhibitors. Although it was shown 
that long-term treatment with a TGF-1 antagonist did not evoke any significant changes in the 
immune system of mice (Yang et al. 2002), the differential effects of inhibitors on TGF- con-
centration and activity need to be carefully considered in order to achieve optimal benefits and 
to avoid undesirable side effects such as tumour promotion. 
3. Profibrotic growth factor receptors and signalling 
The localization of antioxidative preoxiredoxins I-VI has been characterized in normal human 
lung tissue as well as in patients with sarcoidosis and lung cancer (Kinnula et al. 2002, Lehto-
nen et al. 2004). The present results suggest that in the IPF/UIP lungs, activation of peroxire-
doxin II does not occur in the fibroblastic foci but rather in the inflammatory and alveolar 
epithelial cells, which form the main site of the injury. Prx II has been identified as a negative 
modulator of PDGF signalling and Prx II deficiency has been reported to result in enhanced ac-
tivation of PDGF receptor and increased cell proliferation and migration in response to PDGF 
(Choi et al. 2005). In spite of the low Prx II levels in the fibroblastic foci, no marked cell pro-
liferation could be seen in these lesions. Oxidant-related metabolism seemed to co-localize 
with Ki67-expressing proliferating cells predominantly outside the fibroblastic foci. The results 
were surprising, since it is generally believed that the fibroblastic foci are areas of active, ongo-
ing cellular proliferation. 
Oxidative stress has been suggested as a potential contributor to the pathogenesis of IPF (Kin-
nula and Myllärniemi 2008) but Prx oxidation has not been studied extensively in human mate-
rial.  The absence of Prx II oxidation in IPF/UIP when compared to normal lung suggests how-
ever that Prx II oxidation does not relate to the pathogenesis of IPF/UIP. Antioxidant therapies 
in the future might be more effective if they were directed against the inflammatory reactions 
and epithelial injury rather than fibroblast proliferation and the fibroblastic foci.
Although various animal models have been developed, there is yet no single model to repro-
duce all the aspects of the human IPF. One explanation for the poor adaptability of animal 
models into therapeutic trials and clinical practice may be that the widely used mouse bleomy-
cin - or radiation-induced fibrosis models may not mimic human UIP lesions (Borzone et al. 
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2001), which are progressive and often devoid of inflammatory cells. However, intratracheal 
administration of asbestos fibres has been used to develop and characterize an animal model of 
lung fibrosis in which fibrosis evolves slowly and progressively and where the lesions and pro-
file of the compounds in BAL fluid mimic human IPF/UIP (Glassroth et al. 1984).  
Since PDGF mRNA expression is elevated in the lungs of patients with IPF (Nagaoka et al. 
1990), imatinib mesylate was chosen as an inhibitor of the profibrotic effects mediated by 
PDGF, Abl and c-Kit. The results suggest that imatinib mesylate is a potential inhibitor of col-
lagen deposition in crocidolite asbestos-induced pulmonary fibrosis when used at a specific 
dosage (10 mg/kg/day). Imatinib mesylate did not affect BAL fluid neutrophilia which indi-
cates that the specific tyrosine kinase inhibition that it evokes acts directly via inhibition of 
profibrotic signalling, independent of the inflammatory response. Imatinib mesylate has previ-
ously been reported to have both anti-inflammatory and antifibrotic effects in bleomycin-
induced pulmonary fibrosis (Chaudhary et al. 2006). However, bleomycin causes mainly lym-
phocytosis, whereas asbestos-induced pulmonary fibrosis results in inflammation and accumu-
lation of neutrophils which may explain these different effects. No differences were observed 
in the BAL fluid TGF-1 -levels of the imatinib mesylate-treated compared to non-treated 
animals, suggesting that the mechanism of inhibition may not be directly linked to any increase 
or decrease in TGF-1 production. This does not rule out the possibility that imatinib mesylate 
may antagonise TGF-1 activation by decreasing intracellular TGF- -signalling via Abl (Dan-
iels et al. 2004).
Cultured IPF fibroblasts have been reported to have an enhanced migratory capacity (Su-
ganuma et al. 1995) and cells from fibroblastic foci express migratory markers (Chilosi et al. 
2006). However, the results on the apoptotic and growth rates of cultured normal and IPF fi-
broblasts have been somewhat contradictory, possibly due to differences in the technigues and
methods and heterogeneity in the cell populations used (Raghu et al. 1988, Ramos et al. 2001, 
Hetzel et al. 2005). The present study demonstrated that in response to 10% serum, the migra-
tion rate of primary human IPF fibroblasts was slower than that of normal human pulmonary 
fibroblasts, and that PDGF-AB and PDGF-BB were powerful stimulators of this migration. 
Imatinib mesylate inhibited profibrogeneic growth factor–induced IPF fibroblast migration in 
vitro in a concentration-dependent manner. Imatinib mesylate has been proposed to have also 
profibrotic effects since it failed to inhibit myofibroblast accumulation and EMT, and did not 
protect against pulmonary fibrosis when administered during the postinjury repair period of 
bleomycin-induced pulmonary fibrosis (Vittal et al. 2007). An increasing number of reports 
have also described imatinib mesylate-induced interstitial pneumonia in patients with chronic 
myeloid leukaemia or gastrointestinal tumours (Isshiki et al. 2004, Ohnishi et al. 2006). The 
mechanisms responsible for these symptoms remain unclear and further studies will be needed 
to reveal whether imatinib mesylate can cause these adverse effects in patients with IPF or
whether it represents a potentially beneficial drug in the treatment of human IPF. Imatinib me-
sylate may also have benefits in the prevention of asbestosis progression, because asbestos-
exposed patients are carefully monitored and therefore treatment could be initiated when the 
disease is still at an early stage. 
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CONCLUSIONS
Estimations of the BAL fluid MMP-7 protein levels revealed that although MMP-7 is increased 
in IPF/UIP patients when compared to healthy control subjects its elevation is not restricted to 
IPF/UIP and cannot be utilized in differential diagnostics. Inclusion of disease control groups, 
such as patients with prolonged cough, are valuable in studies searching for disease-specific 
diagnostic markers because their inclusion can reveal an overall elevation in the levels of a 
marker originally thought to be specific to a certain disease. 
Analysis of gremlin protein and mRNA expression revealed an increase in IPF/UIP fibroblasts 
and IPF/UIP lung tissue when compared to normal human pulmonary fibroblasts and control 
lung tissue. Although gremlin was highly expressed in pulmonary fibroblasts from IPF/UIP pa-
tients, no corresponding overexpression was found in the skin fibroblasts of scleroderma pa-
tients, suggesting that the overexpression might be a useful indicator of IPF/UIP and lung fi-
brosis rather than fibrosis in general. In lung specimens from patients with IPF/UIP, gremlin 
was detected mainly in the thickened lung parenchyma and in the endothelium of small capil-
laries, whereas in NSIP it was localized predominantly in the alveolar epithelium. This differ-
ence in the localization pattern of gremlin suggests that parenchymal gremlin immunoreactivity 
relates to a UIP-type interstitial pneumonia.
Gremlin mRNA levels were higher in patients with end-stage fibrosis than in patients with 
early disease, suggesting that gremlin might be a marker for more advanced disease stage. Ele-
vated gremlin mRNA levels also correlated with decreased lung function parameters in 
IPF/UIP and NSIP patients indicating that elevated gremlin expression is associated with the 
severity of the disease.
The overall levels of the antioxidant Prx II in the IPF/UIP lung were low and Prx II was local-
ized mainly to the epithelium and alveolar macrophages. There appeared to be no major oxida-
tion of Prx II when compared to normal lung, suggesting that Prx II oxidation does not relate to 
the pathogenesis of IPF/UIP. The amount of Prx II, PDGFRs, nitrotyrosine and the prolifera-
tion marker Ki67 in the fibroblastic foci of IPF/UIP were low or absent. This was surprising 
since it is generally believed that the fibroblastic foci are areas of active, ongoing cellular pro-
liferation. 
Imatinib mesylate was found to be a potential inhibitor of profibrotic effects mediated by 
PDGF, Abl and c-Kit in crocidolite asbestos-induced pulmonary fibrosis and of profibrogeneic 
cytokine–induced IPF fibroblast migration in vitro. Imatinib mesylate might be a potential can-
didate for the prevention of fibroblast accumulation in IPF/UIP and asbestosis when used at a 
specific dosage. It has, however, been proposed to have also profibrotic effects on the epithelial 
cells and myofibroblasts fibroblast proliferation and an increasing number of reports have em-
phasized the adverse effects of imatinib mesylate treatment in patients with chronic myeloid 
leukaemia or gastrointestinal tumours. Further studies will reveal whether imatinib mesylate 
can cause these adverse effects in patients with IPF and whether it actually will be a potential 
drug in the treatment of human IPF.
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